Author Index for Volume 16

Aarhus GN (abst) 224
Abadie A (abst) 94
Abassi A (abst) 893
Abboud HE (abst) 781, 788, 823, 858
Abourizk N (abst) 914
Abourizk NA (abst) 949
Abrams D (abst) 785
Abramson RG (abst) 802
Abras E (abst) 865 (2)
Abu-Hamdan DK (abst) 818
Ackerman GL (abst) 911
Ackrill P (abst) 216
Adam C: *see* VERROUST et al 9
Adamick R (abst) 790
Adams FF (abst) 900
Adams ND (abst) 943
Adamsons R (abst) 948
Adamsons RJ (abst) 949
Adelman RD (abst) 771
Adeniyi A: *see* HENDRICKSE and ADENIYI 64
Adhémar JO (abst) 230
Adhémar JP (abst) 657–658
Adhikari MA (abst) 86
Adir JA (abst) 896
Adler A (abst) 927
Adler S (abst) 813, 924, 927
Adrogué HJ: *see* MADIAS et al 612
Adrogué HJ (abst) 879
Adu D (abst) 660
Affeld K (abst) 217
Agatson A (abst) 890
Agre KL (abst) 798, 953
Agus Z: *see* LAU et al 736
Agus ZS (abst) 837
Ahmad S (abst) 924
Aikawa M (abst) 858
Aime F (abst) 656
Ainsworth SK (abst) 788
Airoldi G (abst) 654
Akbar S (abst) 925
Al-Arif L (abst) 911
Alavi N (abst) 848, 880, 921
Al-Awqati (abst) 809, 811, 872
Al-Bander H (abst) 846
ALBERTINE KH, O'MORCHOE CCC: Distribution and density of the canine renal cortical lymphatic system 470
Albertine KH (abst) 830
Albertini A (abst) 653
Alday B (abst) 884
Alexander EA (abst) 806
Alexander JW: *see* HONG et al 167
Alexandre GPJ (abst) 98, 233
Alfonso L (abst) 652
Alfred H (abst) 891, 899
Alfrey AC (abst) 789
Ali M (abst) 880
Alla V (abst) 846
Allegri L (abst) 232
Allen J (abst) 660
Alleyne GAO (abst) 846
Allison TG (abst) 932
Alloati S (abst) 219, 650
Allock ER (abst) 86
Allon U (abst) 849
Alonso F (abst) 216
Alspaugh M (abst) 945
Alt JM: *see* STOLTE et al 377
Alterhoff G (abst) 224
Alpert H (abst) 778
Alvestrand A (abst) 216, 892
Amend W (abst) 242, 940, 948, 951
Amonette RL (abst) 792
Amos N (abst) 93
Anagnostopoulos T (abst) 812
Anderson C: *see* ROSENBAUM et al 179
Anderson C (abst) 892
Anderson CB (abst) 847
Anderson GH Jr (abst) 873
Anderson J (abst) 825
Anderson R (abst) 868
Anderson RJ (abst) 873
ANDRADE ZA, ROCHA H: Schistosomal glomerulopathy 23
Andre C (abst) 655
Andre JL (abst) 656
Andreasen F (abst) 225
Andrejak M (abst) 219, 655
Andreoli TE: *see* ROSTAND et al 600
Andres GA (abst) 213, 799
Andreucci VE: *see* USBERTI et al 546
Andreucci VE (abst) 220
Andriole VT (abst) 878
Anelli A (abst) 649
Ang KS (abst) 97, 659
Annema A (abst) 532
Antonacci A (abst) 232, 649
Antonello A (abst) 649
Antoniou LD (abst) 880
Antonovych TT (abst) 925
Aoki KR (abst) 798
Apap CR (abst) 533
Appel GB (abst) 946
Appenheimer M (abst) 872
Appleton FM (abst) 847
Arant BS Jr (abst) 937
Arastu MI (abst) 914
Arbeit LA (abst) 870, 903
Ardaillou R (abst) 839, 847
Arfania D: *see* RUBIN et al 619
Arias IM (abst) 773
Arieff AI (abst) 918, 955

Aristimuno GG (abst) . . . 906
Arisz L (abst) . . . 213, 214 (2)
Arnold P (abst) . . . 957
Arnold WC (abst) . . . 865, 950
Aroldi A (abst) . . . 216, 218, 232, 649
Aronow WS (abst) . . . 884
Aronson PS (abst) . . . 805, 820
Arora TS (abst) . . . 914
Arrascue JF (abst) . . . 803, 873
Arruda JAL (abst) 788, 790, 803 (2), 846, 847 (2), 868, 925, 926, 940
Ashouri O (abst) . . . 893
Ashraf N (abst) . . . 918
Asscher AW (abst) . . . 92
Assocs DN (abst) . . . 886
Atkins C (abst) . . . 946
Atkins J (abst) . . . 896
Atkins JL (abst) . . . 810
Atkins RC (abst) . . . 240, 880
Atlas SA (abst) . . . 791
Attallah A (abst) . . . 791
Ausiello DA (abst) . . . 804 (2), 833
Avasthi PS (abst) . . . 771
Avner ED (abst) . . . 877
Avram MM (abst) . . . 217, 881
Aynedjian HS: *see* KURODA et al . . . 561
Ayus J (abst) . . . 881
Ayus JC (abst) . . . 881
Azar S (abst) . . . 791, 792

Babb AL (abst) . . . 239
Babin Ph (abst) . . . 99
Baccaglini U (abst) . . . 651
Backman KA (abst) . . . 819
Badr KF (abst) . . . 783
Bagby SP (abst) . . . 791, 792
Baggio B (abst) . . . 649
Baines A (abst) . . . 804
Baird C (abst) . . . 226
Baker GP (abst) . . . 887
Baker L (abst) . . . 906
Baker LRI (abst) . . . 92
Baker S Jr (abst) . . . 772, 814
Bakker B (abst) . . . 533
Bakker WW (abst) . . . 213
Balaban RS (abst) . . . 804
Balasa RW (abst) . . . 950
Balcke P (abst) . . . 227 (3), 238
Baldamus CA (abst) . . . 891
Baldwin DS (abst) . . . 913, 927, 929
Baldwin M (abst) . . . 803
Balestrieri G (abst) . . . 232
Baluarte G (abst) . . . 721
Banerji MA (abst) . . . 921
Banfi G (abst) . . . 651
Bank N: *see* KURODA et al . . . 561
Bank N: *see* LIEF et al . . . 103
Bankir L (abst) . . . 847
Bansal VK (abst) . . . 895
Barakat AY (abst) . . . 925
Baranowski KL (abst) . . . 844
Baranowski RL (abst) . . . 843, 844, 925
Barbiano di Belgioioso G (abst) . . . 650
Barcenas C (abst) . . . 881
Barcenas CG (abst) . . . 881
Bard M (abst) . . . 868
Bardana EJ (abst) . . . 917
Barg A (abst) . . . 779, 898
Barger AC (abst) . . . 873
Barjon P (abst) . . . 97, 657
Bar-Khayim Y (abst) . . . 823
Barlassina C (abst) . . . 651
Barmeyer FW (abst) . . . 789
Barnes JL (abst) . . . 771, 781
Barnett EV (abst) . . . 798
Barnett MD (abst) . . . 92
Barnett WM (abst) . . . 874
Baron B (abst) . . . 220
Baron M (abst) . . . 99
Baroni A (abst) . . . 654
Barratt TM: *see* HUTTUNEN et al . . . 322
Barrett PQ (abst) . . . 805
Barron J (abst) . . . 216
Barry J (abst) . . . 231 (2)
Barry JM (abst) . . . 940, 946 (2)
Bartlow BG (abst) . . . 913
Bartolotti SR (abst) . . . 92
Bartter FC (abst) . . . 853
Baruch S (abst) . . . 802
Baruch SB (abst) . . . 829
Basgen JM (abst) . . . 786
Baskin S (abst) . . . 894
Batist G (abst) . . . 950
Batlle D (abst) . . . 925, 926, 940
Batsford S (abst) . . . 217
Batuman V (abst) . . . 918
Bauer JH (abst) . . . 918
Baum J (abst) . . . 890
Bauman JW Jr (abst) . . . 781
Baumelou A (abst) . . . 96
Baverel G: *see* LEMIEUX et al . . . 451
Baverel G (abst) . . . 654
Baxter PR (abst) . . . 792
Bazaz L (abst) . . . 953
Bazzato G (abst) . . . 649
Bazzi M (abst) . . . 883
Bean G (abst) . . . 805
Beans E (abst) . . . 779
Beard DC (abst) . . . 866
Beary J (abst) . . . 926
Beasom F (abst) . . . 771
Beau MC (abst) . . . 239, 899
Bec P (abst) . . . 94
Becaus I (abst) . . . 97
Beck CH (abst) . . . 901
Beck N (abst) . . . 848
Becker H (abst) . . . 217, 238
Beckner J (abst) . . . 951
Beehler C (abst) . . . 951
Beeuwkes R III (abst) . . . 805, 840, 873
Beierwaltes WH (abst) . . . 805, 836
Beirne GJ (abst) . . . 926
Belghiti D (abst) . . . 655
Belizon IJ (abst) . . . 851
Bell PD (abst) . . . 806
Belloli S (abst) . . . 218

Bello-Reuss E (abst) 820
Bellorin-Font E (abst) 816, 852
Beltrandi E (abst) 653
Pelzer FO (abst) 903
Bemis JA (abst) 779
Ben Ayed M (abst) 658
Ben Dardeff A (abst) 219
Ben-David M (abst) 888
Bendush B (abst) 778
Benet LZ (abst) 942 (2)
Bénévent D (abst) 241
Bengele HH (abst) 806
Bengfort L (abst) 886
Ben Ischay (abst) 656
Benkovic B (abst) 653
Ben Maiz M (abst) 658
Bennett WM (abst) 231, 773, 775, 917 (2), 934, 940, 946 (2), 947
Bentle L (abst) 868
Bentzel C (abst) 848, 880, 921
Benz G (abst) 218
Beres JA (abst) 943
Berg KJ (abst) 225
Bergfeld MA (abst) 924
Bergstein JM (abst) 926
Bergström J (abst) 216, 892
Berl T (abst) 857, 868, 869, 873, 957
Berliner RW (abst) 809
Berlyne GM (abst) 887, 927
Bernard DB (abst) 774, 903
Berndt TJ (abst) 823
BERNICK JJ, PORT FK, FAVERO MS, BROWN DG: Bacterial and endotoxin permeability of hemodialysis membranes 491
Bernick JJ (abst) 896
Bernstein J: *see* EVAN et al 743
Bernstein M (abst) 953
Bertani T (abst) 652
Berthoux FC (abst) 217, 911
Besarab A (abst) 806, 940
Bettcher KB (abst) 941
Better OS (abst) 849
Betti A (abst) 223
Betzel C (abst) 903
Beynen AK (abst) 862
Bhan AK (abst) 796
Bia M (abst) 917
Biagi BA (abst) 806
Bianchi G (abst) 649, 651
Bianchi M (abst) 793
Biava CB (abst) 927
Biava CG (abst) 931, 939
Bichara M (abst) 658
BIDANI A, CHURCHILL P, FLEISCHMANN L: Sodium-chloride-induced protection in nephrotoxic acute renal failure: Independence from renin . . 481
Bierman MH (abst) 881, 915
Bijnen AB (abst) 234
Bijvoet OLM (abst) 243
Bilbrey G (abst) 897
Binder HJ (abst) 820
Bingham R (abst) 895
Bini A (abst) 896
Birkenhäger WH (abst) 533
Birkhead G (abst) 917
Bischel MD (abst) 950
Bishop E (abst) 86
Bisordi JE (abst) 869
Bistrian B (abst) 950
Bistritz J (abst) 774
Blachley J (abst) 889
Blagg C (abst) 916
Blaine EH (abst) 802
Blanc N (abst) 99
Bland H (abst) 876
Blank S (abst) 89
Blantz RC (abst) 841, 848
Block C (abst) 86
Bloch D (abst) 791
Bloomer HA (abst) 910
Blouch K (abst) 825
Bluestone P (abst) 932
Blumenkrantz MJ (abst) 882 (2), 888
Boer P (abst) 236, 531, 660
Bogusky RT (abst) 776
Bohrer MP: *see* DEEN et al 353
Boland A (abst) 883 (2)
Bolmey S (abst) 948
Bolton WK (abst) 781, 848
BOMMER J, RITZ E, TSCHÖPE W, WALDHERR R, GEBHARDT M: Urinary matrix calculi consisting of microfibrillar protein in patients on maintenance hemodialysis 722
Bommer J (abst) 218
Bond JT (abst) 947
Bondar N (abst) 795
Bonforte G (abst) 649
Bonnard M (abst) 654
Bonnici F (abst) 86
Bonucci E (abst) 653
Boomsma JHB (abst) 531
BOONPUCKNAVIG V, SITPRIJA V: Renal disease in acute Plasmodium falciparum infection in man . 44
Booth BE (abst) 922
Bopp NA (abst) 777
Border WA (abst) 796, 911
Borges H (abst) 882
Borgnino LC (abst) 219
Borsatti A (abst) 649
Bosch JP (abst) 222, 882, 883
Bosio D (abst) 650
Boss JH: *see* ROSENMANN and BOSS 337
Bouissou F (abst) 656
Boulpaep EL (abst) 835
Boulton-Jones M (abst) 92
Bourgoignie JJ (abst) 774, 787 (2), 819 (2), 900, 928
Bourke E (abst) 929
Bouthier M (abst) 812
Bower J (abst) 780, 897
Bowman RL: *see* PASTORIZA-MUNOZ et al 440
BOYLAN JW: Introduction to Symposium 247
Bracchi (abst) . . . . . 651 N.I.
Braden G (abst) 807
Brancaccio D (abst) 216, 218, 649, 653
Branellec A (abst) 657
Brasile L (abst) 862

GENERAL BOOKBINDING CO.
80 328AA 2 013 1 C 2053
QUALITY CONTROL MARK

Brater DC: *see* CHENNAVASIN et al 187
Brater DC (abst) 919
Brautbar N (abst) 807
Bray S (abst) 939
Brayland R (abst) 952
Brazy PC (abst) 807
Brecht HM (abst) 891
Breckenridge WC (abst) 954
Bredgaard M (abst) 224
Breed A (abst) 885
Bregman H (abst) 883 (2)
Brem AS (abst) 807
Brennan DL (abst) 830
Brennan LA Jr (abst) 908
Brenner BM: *see* DEEN et al 353
Brenner BM: *see* ICHIKAWA et al 137
Brenner BM (abst) . . 776, 783, 821 (2), 822, 835, 854, 867
Brentjens J (abst) 799
Brentjens JR (abst) 213
Brescia DJ (abst) 885
Breslau NA (abst) 935
Brewer ED (abst) 919
Bricker NS: *see* ROBSON et al 416
Brickman AS (abst) 919, 954
Briefel G (abst) 899
Brière R: *see* LEMIEUX et al 451
Briggs J (abst) 808
Briggs W (abst) 893
Briggs WA (abst) 883
Brinker K (abst) 849
Brinker KR (abst) 889
Briones J (abst) 914
Broados AE (abst) 956
Brochard D (abst) 659
Brocheriou C (abst) 96
Brodsky WA (abst) 860
Brody PE 881
Brooks CS (abst) 918
Brown (abst) 792
Brown CD (abst) 884, 927
Brown DG: *see* BERNICK et al 491
Brown DM (abst) 786, 808
Brown FG (abst) 901
Brown P: *see* RUBIN et al 619
Brown RL (abst) 843
Brown S (abst) 884
Brown WA (abst) 231
Brown WW: *see* ZENSER et al 688
Broyer M (abst) 96 (2), 656
Brunette MG (abst) 849
Brunner F (abst) 242
Brunner HR (abst) 243
Bruno L (abst) 792
Bruno M (abst) 223
Bruno V (abst) 240
Bruns F (abst) 849, 924
Bruns FJ (abst) 927
Brunzell JD (abst) 888
Bucciarelli E (abst) 652
Buckalew VM (abst) 930 (2)
Buckalew VM Jr (abst) 817, 935
Buckingham BA (abst) 912
Budd M (abst) 954
Buddington B (abst) 789
Buerkert J (abst) 832
Bulger R (abst) 849
Bulger RE (abst) 805
Bulla M (abst) 218
Bunting S (abst) 244
Burch RN (abst) 869, 918
Burckhardt P (abst) 921
Burg MB (abst) 836
BURKE TJ, DUCHIN KL: Glomerular filtration during furosemide diuresis in the dog 672
Burnham T (abst) 925
Burritt MF (abst) 935
Burrows L (abst) 218
Burton BT (abst) 226
Burton H (abst) 892
Bushinsky DA (abst) 808, 875
Busick E (abst) 950
Butkus D (abst) 822, 829
Butt KMH (abst) 884, 948, 949
Buxbaum J (abst) 929

Cabili S (abst) 771, 913, 927, 929
Cade R (abst) 919
Cadnapaphornchai P (abst) 795
Caflisch CR (abst) 815 (2)
Cagnoli L (abst) 653
Cairns SA (abst) 660, 911
Caldicott WJH (abst) 803
Calhoun D (abst) 946
Callaway W (abst) 99
Calmette C (abst) 219, 655
Calne RY (abst) 230
Camacho P (abst) 91
Cambier P (abst) 223, 655
Cameron JS: *see* PARBTANI and CAMERON 53
Cameron JS (abst) 93
Camillieri JP (abst) 658
Cammà M (abst) 240
Campese VM (abst) 951
Campieri C (abst) 219
Camussi C (abst) 650
Camussi G (abst) 650
Canarelli G (abst) 94
Candelora PD (abst) 773
Canenaghi A (abst) 652
Cannella G (abst) 650
Cannon PJ (abst) 830
Cantaluppi A (abst) 216, 649
Canterbury J (abst) 918
Cantwell S (abst) 908
Capparell N (abst) 797, 801 (2)
Cardella C (abst) 928
Cardella CJ (abst) 941
Carey J (abst) 790
CARONE FA, PETERSON DR, OPARIL S, PULLMAN TN: Renal tubular transport and catabolism of proteins and peptides 271
Carone FA (abst) 831
Carozzi S (abst) 651
Carpenter BJ (abst) 942
Carpenter CB (abst) 863, 864 (2), 911, 942
Carretero O (abst) 836

Carrie BJ (abst) . . . 928
Carroll HJ (abst) . . . 895, 921
Carruthers M (abst) . . . 903
Carter GG (abst) . . . 778
Carter M: *see* STERNBERG et al . . . 329
Carter N (abst) . . . 828
Carter NW (abst) . . . 811, 827
Carvalho JS (abst) . . . 808
Carvounis CP (abst) . . . 870 (2)
Carvounis G (abst) . . . 870 (2)
Casado S (abst) . . . 235
Casati S (abst) . . . 218, 649
Case DB (abst) . . . 906
Case N (abst) . . . 639
Castro J (abst) . . . 233
Catizone L (abst) . . . 653
Cattell WR (abst) . . . 92
Catto GRD (abst) . . . 219
Cattran DC (abst) . . . 928 (2)
Cavagnino A (abst) . . . 654
Cavailles C (abst) . . . 658
Cavenaghi A (abst) . . . 651, 652, 653
Cecchetin M (abst) . . . 216
Cemerikic DA (abst) . . . 809
Cerilli J (abst) . . . 862
Cerrai T (abst) . . . 229
Cervenka J (abst) . . . 779, 909 (2), 924
Cestero RVM (abst) . . . 884, 890, 900
Chaimovitz C (abst) . . . 849, 957
Chami J (abst) . . . 864 (2)
Chan JCM (abst) . . . 792, 928
Chan M (abst) . . . 849
Chan W (abst) . . . 804
Chandra M (abst) . . . 893, 903
Chandraratna PAN (abst) . . . 884
Chang CH (abst) . . . 916
Chang ES (abst) . . . 788
Chantrelle B (abst) . . . 809 (2)
Charmes JP (abst) . . . 241
Charney AN (abst) . . . 771, 813
Charpentier B (abst) . . . 95
Charron R (abst) . . . 928
Chase HS Jr (abst) . . . 809
Chatgidakis C (abst) . . . 89
Chatterjee SN (abst) . . . 220
Chatzilias A (abst) . . . 794
Cheema-Dhadli S (abst) . . . 837
Chegai E (abst) . . . 654
Cheigh J (abst) . . . 926
Cheigh JS (abst) . . . 237, 864, (2)
Chen WT (abst) . . . 850, 885, 889
CHENNAVASIN P, SEIWELL R, BRATER DC, LIANG WMM: Pharmacodynamic analysis of the furosemide-probenecid interaction in man . . . 187
Chennavasin P (abst) . . . 919
Cherem L (abst) . . . 802
Chesney RW (abst) . . . 885
Chevalier RL: *see* FINN and CHEVALIER . . . 113
Chia D (abst) . . . 798
Chin WD (abst) . . . 91
Chodirker WB (abst) . . . 928
Chonko A (abst) . . . 771
Chopra S (abst) . . . 772
Chou SY (abst) . . . 851
Christensen CK (abst) . . . 225
CHRISTENSEN EI, MAUNSBACH AB: Effects of dextran on lysosomal ultrastructure and protein digestion in renal proximal tubule . . . 301
Christensen EI (abst) . . . 831
Christensen O (abst) . . . 224
Christiansen E (abst) . . . 222
Chrysant SG (abst) . . . 792
Churchill P: *see* BIDANI et al . . . 481
Churg J: *see* HSU and CHURG . . . 497
Churg J (abst) . . . 941
Cianciaruso B: *see* USBERTI et al . . . 546
Cibboda GF (abst) . . . 232
Ciccarelli C (abst) . . . 653
Claas FHJ (abst) . . . 235
Claret (abst) . . . 239
Claret G (abst) . . . 899
Clark WF (abst) . . . 928
Clarke W (abst) . . . 838
CLARKSON EM, RAW SM, DE WARDENER HE: Further observations on a low-molecular-weight natriuretic substance in the urine of normal man 700
Clayton S (abst) . . . 234
Clements PJ (abst) . . . 910
Clements RS Jr (abst) . . . 834
CLYNE DH, PESCE AJ, THOMPSON RE: Nephrotoxicity of Bence Jones proteins in the rat: Importance of protein isoelectric point . . . 345
Clyne DH: *see* PURTELL et al . . . 366
Clyne DH (abst) . . . 920
Coburn JW (abst) . . . 726, 852, 856, 867, 882 (2), 898, 964
Cochrane C (abst) . . . 951
Cochrum K (abst) . . . 940, 948
Cochrum KC (abst) . . . 942
Coen G (abst) . . . 649
Coevoet B (abst) . . . 219, 222, 228, 655, 656
Cogan MG (abst) . . . 809 (2), 810, 951
Coggins CH (abst) . . . 833
Cohen A (abst) . . . 823, 891
Cohen AH (abst) . . . 796, 876, 911
Cohen AJ (abst) . . . 772, 814
Cohen IM (abst) . . . 895, 904 (2), 907, 909 (2), 914, 922, 924
Cohen J (abst) . . . 89
Cohen JD (abst) . . . 91
Cohen JJ: *see* MADIAS et al . . . 612
Cohen JJ (abst) . . . 808, 815 (2), 875
Cohen SJ (abst) . . . 810
Cole CH (abst) . . . 885
Coleman R (abst) . . . 790
Coleman TG (abst) . . . 793
Coli U (abst) . . . 649
Collins AB (abst) . . . 796
Collins AJ (abst) . . . 885
Colombo G (abst) . . . 232
Colon S (abst) . . . 99
Colsanti G (abst) . . . 650
Colton C (abst) . . . 779
Colussi G (abst) . . . 232
Comty CM (abst) . . . 885, 886
Conger JD (abst) . . . 850
Conley J (abst) . . . 892
Conte G (abst) . . . 220

Conté JJ (abst) . . . 658
Conte-Devolx B (abst) . . . 97
Cook MA (abst) . . . 850
Cook VL (abst) . . . 810
Cooke RC (abst) . . . 910
Coovadia HM (abst) . . . 86
Coppo R (abst) . . . 219, 650 (2)
Corbett WT (abst) . . . 930
Corley KC (abst) . . . 792
Corlianó C (abst) . . . 652
Corry P (abst) . . . 928
Cort JH (abst) . . . 870
Cortes P (abst) . . . 782 (2), 790
Corti C (abst) . . . 654
Corvol P (abst) . . . 658
Cosmides J (abst) . . . 902
Costantino A (abst) . . . 649
Costanzo R: *see* USBERTI et al . . . 546
Costiloe P (abst) . . . 868
Cotterill AM (abst) . . . 92
Cotton S (abst) . . . 892
Cottura C (abst) . . . 650
Coulentianos I (abst) . . . 902
Couser WG (abst) . . . 797, 801 (2)
Coville P (abst) . . . 659
Cox JW (abst) . . . 850
Cox M (abst) . . . 807, 814, 870
Craig R (abst) . . . 951
Cramer D (abst) . . . 862
Creighton WD (abst) . . . 797
Crespo MS (abst) . . . 216
Creter D (abst) . . . 953
Cristinelli L (abst) . . . 650, 653
Critz C (abst) . . . 793
Cronin R (abst) . . . 849, 889
Cronon RE (abst) . . . 865
Crosson AW (abst) . . . 875
Crosson JT (abst) . . . 936
Crowley A (abst) . . . 853
Crumrine PK (abst) . . . 904
Cruz C (abst) . . . 925
Cruz-Soto M (abst) . . . 846
Cundy T (abst) . . . 226
Cuppage F (abst) . . . 772
Currier C (abst) . . . 911, 941
Curt GA (abst) . . . 875, 886
Curtis FK (abst) . . . 892
Curtis JR (abst) . . . 223
Cusi D (abst) . . . 651
Cutler RE: *see* LINDNER et al . . . 158
Cutler RE (abst) . . . 785
Czech W (abst) . . . 227

Dabbagh S (abst) . . . 925
Daha MR (abst) . . . 215
Dal Canton A (abst) . . . 220
Dall'Aglio P (abst) . . . 232
Dallam D (abst) . . . 955
Dalmasso F (abst) . . . 223
Damasso R (abst) . . . 650
Danion JM (abst) . . . 96
Danovitch GM: *see* SCHMIDT and DANOVITCH . . . 590
Danovitch GM (abst) . . . 234
Darby C (abst) . . . 797, 801 (2)
Dark C (abst) . . . 88
Dasgupta MK (abst) . . . 945
Dash A (abst) . . . 92
Dass PD (abst) . . . 810
Daugirdas JT (abst) . . . 850, 885, 889 (2), 895
Davanture P (abst) . . . 95
David D (abst) . . . 882
Davidman M (abst) . . . 786
Davies RO (abst) . . . 802
Davis BB: *see* ZENSER et al . . . 688
Davis JA (abst) . . . 780
Davisdon W (abst) . . . 824, 865
Davison AM (abst) . . . 220, 239, 243
Dawids S (abst) . . . 224
Day H (abst) . . . 851
Day RS (abst) . . . 86
Deane N (abst) . . . 779, 887
De Bastiani PL (abst) . . . 223
Debongnies JC (abst) . . . 98
De Chadarevian JP (abst) . . . 925
Dechenne C (abst) . . . 656
DEEN WM, BOHRER MP, BRENNER BM: Macromolecule transport across glomerular capillaries: Application of pore theory . . . 353
Deen WM (abst) . . . 811
De Ferrari G (abst) . . . 651
De Fremont JP (abst) . . . 222, 228, 656
DeFronzo R (abst) . . . 917, 952
Deftos LJ (abst) . . . 919
De Gaetano G (abst) . . . 236, 651, 653, 922
Degoulet P (abst) . . . 656
De Graeff J (abst) . . . 215, 225
De Grandpré P: *see* STERNBERG et al . . . 329
DeGuzman A (abst) . . . 806
Dehner LP (abst) . . . 948
Deitch M (abst) . . . 908
Delaney V (abst) . . . 929
Delano BG (abst) . . . 887
Delavelle F (abst) . . . 94
De Leeuw PW (abst) . . . 533
DeLeeuw PW (abst) . . . 857
De Leo M (abst) . . . 654
Del Greco F (abst) . . . 896, 903, 947
D'Elia J (abst) . . . 914, 950
D'Elia JA (abst) . . . 875, 886, 949
Delling G (abst) . . . 218
Delmez J (abst) . . . 886
DelMonte ML (abst) . . . 895
Delons S (abst) . . . 656
De March M (abst) . . . 650
De Mendonca M (abst) . . . 656
De Meo F (abst) . . . 240
Demetriou J (abst) . . . 779
Dennis VW (abst) . . . 804, 807
DeOreo P: *see* LAU et al . . . 726
Deprettere AJR: *see* VAN ACKER et al . . . 196
De Reutter AS (abst) . . . 218
De Rouffignac C (abst) . . . 873
Deschodt G (abst) . . . 239, 899
De Sousa RC (abst) . . . 812, 872
Desplan C (abst) . . . 219, 655
Deteix P (abst) . . . 99

De Torrente A (abst) 857
Deutch J (abst) 867
De Veber GA (abst) 941
DeVecchi A (abst) 649
De Wardener HE: *see* CLARKSON et al 710
De Wardener HE (abst) 223
Deyskes GG (abst) 531 (2)
Diamond I (abst) 923
DiBona GF (abst) 795, 852
Dick PP (abst) 902
Dickerman R (abst) 943, 946
Dickmann D (abst) 873
Dirks JH (abst) 845 (2)
DiScala VA (abst) 871, 872
Disler P (abst) 87, 89
DiTella P (abst) 844
Ditlove J (abst) 841
Dixon FJ (abst) 797
Dixon TE (abst) 811
Dobson J (abst) 660
DOBYAN DC, LACY FB, JAMISON RL: Suppression of potassium-recycling in the renal medulla by short-term potassium deprivation 704
Dobyan DC (abst) 772, 803, 873
Dodds H (abst) 900
Dodds K (abst) 900
Dogliani M (abst) 652
Dohrman B (abst) 221
Dols LCW (abst) 532
Dombros N (abst) 234
Donadio JV (abst) 915
Donadio JV Jr (abst) 788
Donati MB (abst) 653, 796, 922
Dongradi G (abst) 220
Donker A (abst) 242
Donker AJM (abst) 214, 236, 532, 904
Dorhout Mees EJ (abst) 236, 531, 660
Dossetor JB (abst) 221, 941, 945
Doucet A (abst) 811
Dougados M (abst) 657
Douglas JF (abst) 231
Dousa TP (abst) 781, 784 (2), 788, 812, 822, 823, 839, 855, 858
Doyle K (abst) 810
DRATWA M, LEFURGEY A, TISHER CC: Effect of vasopressin and serosal hypertonicity on toad urinary bladder 695
Dratwa M (abst) 94
Dreikorn K (abst) 221
Dreslinski GR (abst) 906
Drüeke T (abst) 221, 244
Drummond KN (abst) 816
D'Souza JP (abst) 884
Duarte C (abst) 844
Dubois CH (abst) 95, 97, 656
DuBose T (abst) 889
DuBose TD (abst) 811, 827
Duca R (abst) 242, 440, 948
Duchin KL: *see* BURKE and DUCHIN 672
Duckworth WC: *see* RABKIN et al 433
Duckworth WC (abst) 833
Ducomb M (abst) 805
Ducros J (abst) 98
Duffy DP (abst) 226
Dumler F (abst) 782 (2), 790
Dunn MJ (abst) 793, 819, 858
Durham JH (abst) 860
Dürr JA (abst) 877
Dusing R (abst) 825, 871 (2), 872
Dutta S (abst) 868
Dysart NK (abst) 920
Dytko G (abst) 803 (2), 847 (2), 868

Eales L (abst) 86
Earley LE (abst) 799
Earnest WR (abst) 774, 843, 844 (2)
Earnshaw M (abst) 226
Eberle K (abst) 226
Ebert TH (abst) 876
Eby BK (abst) 851
Eckel R (abst) 819
Edelman A (abst) 812
Edward N (abst) 219, 235
Edwards BR (abst) 814, 871
Edwards KDG (abst) 789
Edwards RM (abst) 784 (2), 812, 822
Eeckhaut W (abst) 533
Egan JD (abst) 881, 915
Egido J (abst) 216, 228
Ehlers SM (abst) 915
Ehrich JHH (abst) 789
Eidal C (abst) 917
Eigenbrodt E (abst) 877
Eiser AR (abst) 793
Eknoyan G (abst) 955
Elema JD (abst) 214
Elliott S (abst) 880
Elliott WC (abst) 773, 775, 917
Ellis D (abst) 904
Ellis HA (abst) 230
Ellis S (abst) 872
El Matri A (abst) 658
El-Mofty SK (abst) 902
Emmanouel D (abst) 866
Emery HM (abst) 938
Emmet M (abst) 886, 889
Endeman HJ (abst) 236
Engle JE (abst) 866
Entman ML (abst) 860
Ephraim KH (abst) 236
Epstein FH (abst) 874
Epstein M (abst) 920
Erickson AL (abst) 869
Erickson SB (abst) 929
Ernst CB (abst) 825
Ernst W (abst) 891
Espinel CH (abst) 941
Estes NM (abst) 886
Etheredge EE (abst) 847
Ettenger R (abst) 241
Ettinger KV (abst) 219
EVAN AP, GARDNER KD JR, BERNSTEIN J: Polypoid and papillary epithelial hyperplasia: A potential cause of ductal obstruction in adult polycystic disease 743
Evan AP (abst) 771, 786, 843, 902

Evans DB (abst) 230
Evans RM (abst) 802
Eyler W (abst) 944

Faba R (abst) 795
Fabre J (abst) 95
Fagioli F (abst) 223
Fagiolo U (abst) 649
Falcão HA (abst) 875 (2)
Falke HE (abst) 533
Fanelli GM Jr (abst) 812
Fanestil DD (abst) 831
Fang LST (abst) 876, 887
Fang V (abst) 816, 866
Faraggiana T (abst) 861
Farewell VT (abst) 892
Farinelli A (abst) 223
Farnsworth MA (abst) 940
Farquhar MG (abst) 823
Fassbinder W (abst) 891
Faubert PF (abst) 851
Favaro S (abst) 649
Favero MS: *see* Bernick et al 491
Favero MS (abst) 887
Favre H (abst) 99
Favrod-Coune ChA (abst) 812
Fayemi AO (abst) 880
Feder E (abst) 227
Federico S: *see* Usberti et al 546
Feduska N (abst) 242, 940, 948
Feiner HD (abst) 929 (2)
Feinfeld DA (abst) 217, 773
Feinroth M (abst) 887
Feinroth MV (abst) 887, 927
Feinstein E (abst) 828
Feld LG: *see* Galaske et al 394
Feldman GM (abst) 813
Fellner SK (abst) 923
Felsenfeld AJ (abst) 952
Felt J, Richard C, McCaffrey C, Levy M: Peritoneal clearance of creatinine and inulin during dialysis in dogs: Effect of splanchnic vasodilators 459
Felts JH (abst) 817
Fendler J (abst) 220
Fennell JS (abst) 800
Fennell RS (abst) 952
Fenton S (abst) 892
Ferguson CW (abst) 949
Ferguson E (abst) 865
Ferguson RK (abst) 802
Feriozzi F (abst) 240
Fernandes M (abst) 793
Fernandez P (abst) 813
Fernández-Repollet E (abst) 833
Ferrari P (abst) 651
Ferrario F (abst) 650
Ferris TF (abst) 850
Fiaschi E (abst) 649
Figueiredo J: *see* Maack et al 251
Fine L (abst) 865
Fine LG (abst) 813, 823
Fine RN (abst) 241, 912
Finkelstein FO (abst) 891
Finn WF, Chevalier RL: Recovery from postischemic acute renal failure in the rat 113
Finn WF (abst) 773
First MR: *see* Hong et al 167
First MR (abst) 930
Fischer E (abst) 221
Fish AJ (abst) 851, 920, 931
Fisher VJ (abst) 890
Fitzgerald F (abst) 954
Fitzpatrick R (abst) 915
Flamenbaum W (abst) 772, 855
Flanigan WJ (abst) 834
Flather JN (abst) 92
Fleischmann L: *see* Bidani et al 481
Fleischmann LE (abst) 916
Fleishner GM (abst) 773
Fleuren GJ (abst) 531
Fleurew GJ (abst) 213
Flier SR (abst) 821
Flynn CT (abst) 221
Foellmer H (abst) 789
Foidart J (abst) 839
Foidart JB (abst) 95, 97, 656
Foidart JM (abst) 95, 801
Folkert V (abst) 858
Fong HJ (abst) 876
Fonteyne E (abst) 97
Forastieri L e Coll (abst) 653
Forbes RDC (abst) 862
Ford CA (abst) 779
Forissier M (abst) 654
Forrest JN Jr (abst) 956
Forristal J: *see* Wyatt et al 505
Fortina F (abst) 654
Fotino M (abst) 237, 864 (2)
Fouchard M (abst) 658
Fourcade J (abst) 97, 656
Fournié GJ (abst) 97, 658
Fournier A (abst) 219, 222, 228, 655, 656
Fraley DS (abst) 813, 924, 927
Francis G (abst) 885
Francisco LL (abst) 852
Frank J (abst) 217
Frank LR (abst) 933
Frankel H (abst) 894
Franki N (abst) 874
Franks CJ (abst) 775
Franz JP (abst) 932
Frascino J (abst) 880
Fraser RA (abst) 219
Fray JCS (abst) 772, 814
Freed ED (abst) 86
Freedlender AE (abst) 773
Freedman LR (abst) 921
Freeman RB (abst) 922
Freitag J (abst) 852, 924
Frey BM (abst) 942 (2)
Frey FJ (abst) 942 (2)
Friedler RM (abst) 817 (2)
Friedman A (abst) 885
Friedman EA (abst) 867, 884, 887, 895, 927, 936
Fries D (abst) 95, 655

Frigon R (abst) 779
Frindt G (abst) 814
Frizelle K (abst) 86
Frohlich ED (abst) 906
Frohnert PP (abst) 784
Frommer P (abst) 881
Fruchaud G (abst) 657
Frutos M (abst) 235
Fuiano G (abst) 220
Fuller L (abst) 863
Furman KI (abst) 86
Furst DA (abst) 910
Fürst P (abst) 216, 892

Gafter U (abst) 852
Gagnadoux MF (abst) 96, 656
Gagne A (abst) 217, 911
Gahl G (abst) 238
Gailiunas P (abst) 942, 943, 944 (2), 946
Galarza R (abst) 861
GALASKE RG, VAN LIEW JB, FELD LG: Filtration and reabsorption of endogenous low-molecular-weight protein in the rat kidney 394
Galla JH (abst) 824, 825, 852, 879, 933
Galletti G (abst) 649
Gallice P (abst) 97
Gallo GR (abst) 929 (2)
Galmozzi C (abst) 216, 218, 649
Gan A (abst) 881
Gan AC (abst) 217
Gandhi VC (abst) 850, 885, 889
Garavoy M (abst) 944
Garay RP (abst) 95, 656
Garcia G (abst) 930
Gardin JP (abst) 658
Gardner KD Jr: *see* EVAN et al 733
Gardner KD Jr (abst) 902
Garibotto G (abst) 651
Garin E (abst) 952
Garovoy MR (abst) 911, 942
Garrett BN (abst) 905 (2)
Garrett J (abst) 794
Gatta A (abst) 651
Gatti M (abst) 651
Gaudio KM (abst) 930
Gaultier J (abst) 222
Gavellas G (abst) 890, 918
Gavras H (abst) 243
Gazengel C (abst) 657
Geary DF (abst) 952
Gebhardt M: *see* BOMMER et al 722
Geczy M (abst) 908
Geheb M (abst) 807, 814
Gehrig T (abst) 913
Geis WP (abst) 889
Gelfand MC (abst) 883 (2), 912, 933, 950
Gellai M (abst) 814
Gelman ML (abst) 905
Genin C (abst) 217, 911
Gennari FJ (abst) 815 (2)
Genovesio R (abst) 650
George J (abst) 891
George JP (abst) 815
Germuth FG Jr (abst) 782
Geronemus R (abst) 222, 882, 883
Gerstoft J (abst) 222
Giacchino F (abst) 219, 650
Giacchino J (abst) 889
Giachino C (abst) 652
Giammarco R (abst) 815
Gibbs PS (abst) 795
Gibney R (abst) 781
Gibson T (abst) 951
Giddings J: *see* MACIVER et al 632
Giebisch G (abst) 806, 839
Giebisch GH (abst) 809
Gifford RW Jr (abst) 908
Gilbert DN (abst) 773, 775
Gilbert E (abst) 885
Gilbert P (abst) 787
Gilboa N (abst) 782
Giles GR (abst) 220, 243
Gill JM (abst) 853
Gill TJ III (abst) 862
Gilley K (abst) 897
Gilli P (abst) 223
Gingerich R (abst) 947
Ginsberg D (abst) 858
Ginzler EM (abst) 936
Giorcelli G (abst) 223
Giustina G (abst) 653
Glabman S (abst) 222, 882, 883
Glänzer K (abst) 872
Glasser RJ (abst) 783
Glassock RJ (abst) 911
Gleichmann E (abst) 213
Gleim GW (abst) 910
Glöckner WM (abst) 239
Gluck S (abst) 872
Glueck HI (abst) 931
Glynn RD (abst) 821 (2), 854
Godon JP (abst) 223, 655
Goetz FC (abst) 948
GoGuen J (abst) 911
Gohara AP (abst) 786
GOLBUS SM, WILSON CB: Experimental glomerulonephritis induced by in situ formation of immune complexes in glomerular capillary wall 148
Golbus SM (abst) 797
Gold CH (abst) 87
Gold J (abst) 908
Gold ME (abst) 790
Goldby FS (abst) 660
Golden P (abst) 816
Goldfarb S: *see* LAU et al 726
Goldfarb S (abst) 816
Goldman J (abst) 790
Goldschmidt Z (abst) 888
Goldsmith C (abst) 819, 863
Goldstein DA (abst) 920
Goldstein M (abst) 817, 837
Goldstein MB (abst) 860
Golper TA (abst) 917
Gombos EA (abst) 913, 927
Gomez-Sanchez C (abst) 889
Gonwa TA (abst) 930 (2)

Gonzalez FM (abst) 780, 945
Goodall A (abst) 93
Goodman A (abst) 923
Goodman WG: *see* LINDNER et al 158
Goodyer PR (abst) 816
Gordon JS (abst) 649
Gordon M (abst) 223
Gori D (abst) 651
Gorman J (abst) 864 (2)
Gotch F (abst) 887
Gotschall JL (abst) 879
Gottheiner TI (abst) 816
Gougoux A: *see* LEMIEUX et al 451
Gougoux A (abst) 817
Gower PE (abst) 223
Gradowska L (abst) 237
Graefe U (abst) 224
Graf H (abst) 224
Graham R (abst) 944
Graindorge P (abst) 95
Grantham J (abst) 851
Grasset D (abst) 657
Grassetto M (abst) 651
Gray B (abst) 837
Gray DK (abst) 791
Graziani G (abst) 216, 218, 232, 649
Green HH (abst) 956
Greenwalt A (abst) 816
Gregory M (abst) 91
Gregory MC (abst) 90
Gretes JC: *see* ROSTAND et al 600
Grevat A (abst) 97
Griffiths WC (abst) 923
Grishman E (abst) 861
Griswold W (abst) 938
Grodstein G (abst) 952, 953
Grodstein GP (abst) 882 (2), 888
Grond J (abst) 213, 531
Groshong TD (abst) 876
Gross D (abst) 802
Grossman R (abst) 814
Grosso A (abst) 872
Gruber KA (abst) 817
Grundy S (abst) 868
GRUPE WE: Relapsing nephrotic syndrome in childhood 75
Grupe WE (abst) 797
Guasco R (abst) 220
Gubler MC (abst) 96, 655
Guéris J (abst) 222, 656
Guerra L (abst) 650, 651
Guggenheim S (abst) 873
Guicheney P (abst) 656
Guignard JP (abst) 243
Gullberg CA (abst) 898
Gullner HG (abst) 853
Guntupalli J (abst) 943
Gura V (abst) 817 (2), 888, 953
Gurland HJ (abst) 217
Gushwa L (abst) 848
Gushwa LC (abst) 841
Gutierrez L (abst) 940
Gutman RA (abst) 952
Gutmann FD (abst) 853, 890
Gutmann RD (abst) 862, 943
Guyton AC (abst) 793, 845

Haas LB (abst) 888
Haas S (abst) 658
Habib R (abst) 913
Haddad B (abst) 918
Hadjaissa A (abst) 98
Haimov M (abst) 218
Halbwachs L (abst) 657
Haldimann B (abst) 920
Hall BM (abst) 863
Hall DA (abst) 818
Hall JE (abst) 793
Hall PW (abst) 853
Hall-Craggs M (abst) 948
Halloran PF (abst) 863
Halperin M (abst) 817, 837
Halperin ML (abst) 860
Halushka PV (abst) 869
Hamburger RJ (abst) 772, 774, 844, 855
Hamilton GW (abst) 915
Hamilton RH (abst) 935
Hamilton RW (abst) 930
Hammeke M (abst) 915
Hammeke MD (abst) 881
Hammer M (abst) 224
Hammerman MR (abst) 818
Hamoui T: *see* OOI et al 681
Handler J (abst) 822
Hanley MJ (abst) 774
Hano JE (abst) 850, 885, 889 (2), 895
Hansen AaP (abst) 224
Hansen HE (abst) 224, 225
Hardin JM (abst) 228
Harding M (abst) 941
Hardy MA (abst) 818, 819 (2), 946
Harker LA (abst) 915
Harmanci MC (abst) 871
Harmon WE (abst) 797
Harrelson JM (abst) 952
Harrington AR (abst) 953
Harrington JT (abst) 875
Harris AP (abst) 905
Harris RH (abst) 853
Harrison A (abst) 952
Harrison HL (abst) 921
Hartenbower D (abst) 899
Harter H (abst) 866, 886, 947
Haschmeyer R (abst) 237
Hassid A (abst) 793, 819
Haussler MR (abst) 852
Hautier MB (abst) 656
Hays E (abst) 798
Hays RM (abst) 869, 874
Hays S (abst) 790
Hayslett JP (abst) 819, 820
Hayward A (abst) 87 (2)
Hebert L (abst) 862
Hebert LA (abst) 943
Hecox K (abst) 877
Hedger R (abst) 926
Hedges JC (abst) 934
Heilskov NSC (abst) 225

Heinz A (abst) 851
Heinzerling R (abst) 925
Helderman H (abst) 942, 946
Helderman JH: *see* ROWE et al 719
Helderman JH (abst) 943, 944 (3)
Helfrich GB (abst) 941, 950
Hellems E (abst) 780, 897
Helman SI (abst) 824
Helseth H (abst) 885
Henderson L (abst) 779, 868, 798
Henderson LW (abst) 779
HENDRICKSE RG, ADENIYI A: Quartan malarial nephrotic syndrome in children 64
Hem GKVD (abst) 214
Hené RJ (abst) 225
Henrich W (abst) 849, 889
Henriquez C (abst) 867
Henry DP (abst) 795, 825
Henry H (abst) 828
Heptinstall RH (abst) 859
Herbst DV (abst) 778
Hermann J (abst) 909
Hernandez G (abst) 820
Hernando L (abst) 216, 228, 235
Herrmann R (abst) 871
Heublein DM (abst) 855
Heyman S (abst) 877
Heynen G (abst) 226
Hibbard J (abst) 221
Higashi Y (abst) 820
Higgins MR (abst) 221
Hilberman M (abst) 878
Hill AVL (abst) 876, 888
Hill CM (abst) 231
Hirbec G (abst) 655, 657
Hirsch SR (abst) 927
Hirszel P: *see* MAHER et al 130
Hocks J (abst) 882
Hodges G (abst) 772
Hoedemaeker PJ (abst) 213, 214, 531, 534
Hoey J (abst) 936
Hoffman D (abst) 890
Hoffsten P (abst) 947 (2)
Hogg RJ (abst) 977, 914
Holland FF (abst) 226
Hollenberg NK (abst) 778, 857, 944
Holley KE (abst) 915, 938
Holliday J (abst) 862
Holliday MA (abst) 950
Hollsworth SR (abst) 783, 797
Holmberg C (abst) 820
Hölscher F (abst) 228
Holtmann B (abst) 886
HONG CD, KAPOOR BS, FIRST MR, POLLAK VE, ALEXANDER JW: Fractional excretion of sodium after renal transplantation 167
Hong CD (abst) 878, 930
Hong J (abst) 948
Hong JH (abst) 949
Ho S (abst) 848
Hook JB (abst) 830
Hoof JPv (abst) 225
Hopper J Jr (abst) 927, 931, 939
Horcajada C (abst) 235
Horn AC (abst) 216
Hornych A (abst) 657
Horowitz GL: *see* MADIAS et al 612
Horvath F (abst) 895
Hostetter TH (abst) 857
Hou SH (abst) 875
HOUBA V: Experimental renal disease due to schistosomiasis 30
HOUBA V: Immunologic aspects of renal lesions associated with malaria 3
Hough WA (abst) 935
Houghton DA (abst) 775
Houghton DC (abst) 773
Hourani MR (abst) 779
Houser MT (abst) 931
Houston B (abst) 823
Houwert DA (abst) 225
Howard T (abst) 866
Hoyer J (abst) 803
HOYER JR, SEILER MW: Pathophysiology of Tamm-Horsfall protein 279
Hoyer JR (abst) 854
Hricak H (abst) 944
Hruska K (abst) 947 (2)
Hruska KA: *see* ROSENBAUM et al 179
Hruska KA (abst) 818, 867, 902, 924
Hseih J (abst) 788, 803
Hsu A (abst) 912
Hsu CH (abst) 777
Hsu HC (abst) 941
HSU HC, CHURG J: Glomerular microfibrilis in renal disease: A comparative electron microscopic study 497
Huang C (abst) 903
Huber G (abst) 814, 870
Hudson G (abst) 87, 88
Hughes S (abst) 233
Hull A (abst) 886, 943, 944 (2), 946
Hull AR (abst) 889
Hull J (abst) 891
Hulme B: *see* TIGGELER et al 312
Hulter HN (abst) 821 (2), 854 (3), 858
Humayun H (abst) 885, 889
Humes HD (abst) 778, 860, 862
Humes RD (abst) 776
Humphreys MH (abst) 846, 898
Hunsicker LG (abst) 783
Hurtubise PE (abst) 912
Huseman R (abst) 788
Huser J (abst) 771, 786, 843
HUTT MSR: Introduction 1
HUTTUNEN NP, TURNER MW, BARRATT TM: Physicochemical characteristics of glomerular basement membrane antigens in urine 322
Huysmans FTM (abst) 214, 532
Hwang KH (abst) 787 (2)

Iancu M (abst) 881
ICHIKAWA I, MIELE JF, BRENNER BM: Reversal of renal cortical actions of angiotensin II by verapamil and manganese 137
Ichikawa I (abst) 776, 783, 821, 835, 854
Idatte JM (abst) 220
Ideura T (abst) 777

Ihle BU (abst) . . . 940
Iiono Y (abst) 821, 822
Ilstrup DM (abst) . . . 912
Imbasciati E (abst) 650 651
Imbs JL (abst) . . . 96
Ince A (abst) . . . 919
Ing TS (abst) 850, 885, 889 (2), 895
Ingelfinger JR: *see* Robson et al . . . 416
Ingelfinger JR (abst) 803, 877
Inou T (abst) . . . 235
Ippoliti A (abst) . . . 952
Iravani A (abst) . . . 952
Irvin JD (abst) . . . 802
Isaacs M (abst) . . . 898
Isaacson LC (abst) . . . 90
Issa P (abst) . . . 213
Iwai J (abst) 791, 792, 796
Iwaki Y (abst) . . . 948
Iwanami S (abst) . . . 241
Izui S (abst) . . . 798

Jablonsky JP (abst) . . . 97
Jackson B (abst) . . . 931
Jackson BA (abst) 784 (2), 812, 822
Jackson TE (abst) . . . 845
Jacob AI (abst) 774, 890, 918
Jacobs C (abst) 98, 772, 879
Jacobs JJ Jr (abst) . . . 949
Jacobsen FK (abst) . . . 225
Jacobson HR (abst) 820, 822, 827
Jacq D (abst) . . . 98
Jacques C (abst) . . . 657
Jacques L (abst) . . . 95
Jadot C (abst) . . . 242
Jaeger P (abst) . . . 921
Jager BV: *see* Robson et al . . . 416
Jahn HA (abst) . . . 898
Jain VK (abst) 890, 900
James E (abst) . . . 876
Jamison RL, Robertson CR: Recent formulations of the urinary concentrating mechanism: A status report . . . 537
Jamison RL: *see* Dobyan et al . . . 704
Jamison RL (abst) 803, 873
Jankowitz PJ (abst) . . . 88
Jarrett RJ (abst) . . . 93
Jarvis W (abst) . . . 791
Jenkins PG (abst) . . . 890
Jensen P (abst) . . . 891
Jermanovich N (abst) . . . 784
Jetmore AB (abst) . . . 838
Jimenez S (abst) . . . 799
Johns C (abst) . . . 815 (2)
Johnson CM, Wilson DM, O'Fallon WM, Malek RS, Kurland LT: Renal stone epidemiology: A 25-year study in Rochester, Minnesota . 624
Johnson D (abst) . . . 938
Johnson J (abst) . . . 822
Johnson M (abst) . . . 819
Johnson S (abst) . . . 796
Johnson V: *see* Maack et al . . . 251
Johnson WJ (abst) . . . 784
Johnston PA (abst) . . . 774, 903
Johnston M (abst) . . . 928
Jones AS (abst) . . . 876
Jones D (abst) . . . 784
Jones JW (abst) . . . 854
Jones MR (abst) . . . 955
Jones Q (abst) . . . 780, 897
Jonquet O (abst) . . . 656–657
Jordan SC (abst) . . . 912
Jørstad S (abst) . . . 225
Josso F (abst) . . . 657
Jost JO (abst) . . . 916
Julka NK (abst) . . . 803
Jungers P (abst) . . . 244, 657
Junor BJR (abst) . . . 219

Kablitz C (abst) . . . 226
Kachadorian WA (abst) . . . 871, 872, 873
Kager JCGM (abst) . . . 937
Kahn AJ (abst) . . . 856
Kahn JC (abst) . . . 220
Kahn T (abst) . . . 222, 829, 855, 882, 883
Kaiser BA (abst) . . . 945
Kaji D (abst) . . . 855
Kalbfleisch J (abst) . . . 943
Kaldany A (abst) . . . 875, 886, 914, 949, 950
Kalff MW (abst) . . . 225, 235
Kalk WJ (abst) . . . 87
Kalman S (abst) . . . 879
Kaloyanides G (abst) . . . 870
Kaloyanides GJ: *see* Pastoriza-Munoz et al . . . 440
Kamm DE (abst) . . . 953
Kamoun P (abst) . . . 244
Kanayama M (abst) . . . 894
Kanis JA (abst) . . . 226
Kant KS (abst) . . . 878, 931
Kant SK (abst) . . . 930
Kanwar YS (abst) . . . 823
Kaplan G (abst) . . . 938
Kaplan M (abst) . . . 819
Kaplan NM (abst) . . . 905 (2)
Kapoor BS: *see* Hong et al . . . 167
Kardos G (abst) . . . 894
Karl I (abst) . . . 866
Karlinsky ML (abst) . . . 289
Karniski L (abst) . . . 772
Karnovsky MJ: *see* Kreisberg et al . . . 290
Karnovsky MJ: *see* Schwartz et al . . . 577
Karnovsky MJ (abst) . . . 804, 825
Kashgarian M (abst) . . . 776, 930
Kass EH: An approach to the management of resistant urinary infections . . . 204
Kater L (abst) . . . 225
Katirtzoglou A (abst) . . . 234, 780, 954
Katz A (abst) . . . 866, 941
Katz AI (abst) . . . 811
Katz LA (abst) . . . 890, 929
Katz SM (abst) . . . 793
Kau ST: *see* Maack et al . . . 251
Kauffman HM (abst) . . . 943
Kaufman A (abst) . . . 829
Kaufman JS (abst) . . . 772, 855
Kaye M: *see* Somerville and Kaye . . . 552
Kaye M (abst) . . . 226

Kaye WA (abst) 923
Keane WF (abst) 783, 784, 786, 800, 936
Keeton GR (abst) 88
Keinknecht D (abst) 658
Keiser HR (abst) 785
Kelley J (abst) 778
Kelley VE (abst) 798
Kelly G (abst) 879
Kelly TJ (abst) 779, 780
Kelsch RC (abst) 860
Kempson SA (abst) 823, 855
Kennedy L (abst) 233
Kennedy TL (abst) 906
Kermanac HC (abst) 656
Kerr D (abst) 230
Kerr DNS (abst) 230
Kesler P (abst) 859
Kheirbek AO (abst) 885
Kher K (abst) 932
Khumalo EN (abst) 86
Kienstra RA: *see* ROBSON et al 416
Kihara K (abst) 235
Kijlstra A (abst) 215
Kiley J (abst) 780
Kim JK (abst) 784
Kim Y (abst) 851
Kimberly R (abst) 926
King RD (abst) 781
King VF (abst) 802, 829
Kinter LB (abst) 873
Kirchner KA (abst) 824, 852
Kirk KA: *see* ROSTAND et al 590
Kirschbaum B (abst) 877
Kirschbaum BB (abst) 829
Kirschenbaum M (abst) 873
Kirschenbaum MA (abst) 785
Kirson I (abst) 798
Kirson IJ (abst) 912
Kjellstrand C (abst) 882
Klahr S: *see* ROSENBAUM et al 179
Klahr S (abst) 802, 816, 852, 866, 947 (2)
Klare B (abst) 232
Klein E (abst) 226
Klein K (abst) 865
Klein KL (abst) 824, 841
Kleinknecht C (abst) 96
Kleinknecht D (abst) 230
Kleinman J (abst) 829
Kliger AS (abst) 891
Klotman PE (abst) 855
Kluthe R (abst) 217
Knapowski J (abst) 227
Knapp MS (abst) 243
Knepshield JH (abst) 883 (2), 933, 950
Knight D (abst) 805
KNIGHT TF, SENEKJIAN HO, TAYLOR K, STEPLOCK DA, WEINMAN EJ: Renal transport of oxalate: Effects of diuretics, uric acid, and calcium . . . 572
Knight TF (abst) 824, 837, 843
Knoll O (abst) 224
Knox FG (abst) 823, 838
Knochel JO (abst) 865
Knutson DW (abst) 798 (2)
Koch KM (abst) 891
Kodlin D (abst) 945
Koene RAP (abst) 214, 532
Koeppen BM (abst) 824
Kogut MD (abst) 912
Koide H (abst) 785
Kokko JP (abst) 820, 827, 874
Kolff WJ (abst) 226
Kondelis NP (abst) 950
Konieczkowski M (abst) 793
Koop H (abst) 237
Koornhof HJ (abst) 86
Kootstra G (abst) 240
Kopp KF (abst) 877
Kopple JD (abst) 882 (2), 888, 952, 953, 955
Kopsa H (abst) 227 (3), 238
Korkor A (abst) 867
Kosek J (abst) 772
Kotchen TA (abst) 825, 852
Kothari T (abst) 900
Kourilsky O: *see* VERROUST et al 9
Kourilsky O (abst) 97
Kovarik J (abst) 224
Kovithavongs T (abst) 221, 941, 945
Krahenbuhl B (abst) 95
Kramer HJ (abst) 825, 871 (2), 872
Kramer MS (abst) 897
Kramer NC (abst) 928
Kramer P (abst) 228, 231
Krause JZ (abst) 891
Kraut JA (abst) 852
Kraut P (abst) 89
Krayneck J (abst) 901
Kreeb G (abst) 797
KREISBERG JI, WAYNE DB, KARNOVSKY MJ: Rapid and focal loss of negative charge associated with mononuclear cell infiltration early in nephrotoxic serum nephritis 290
Kreisberg JI (abst) 804
Kremp O (abst) 657
Krieger JN (abst) 945
Krom RAF (abst) 240
Kronheim S (abst) 91
Krutzik S (abst) 231 (2), 917 (2), 946 (2), 947
Krzyzaniak K (abst) 825
Ku A (abst) 861
Kubota T (abst) 806
Kumar P (abst) 945
Kumar S (abst) 891
Kumin GD (abst) 878
Kunau R (abst) 775, 826
Kurland LT: *see* JOHNSON et al 624
KURODA S, AYNEDJIAN HS, BANK N: A micropuncture study of renal sodium retention in nephrotic syndrome in rats: Evidence for increased resistance to tubular fluid flow 561
Kurokawa K (abst) 824, 841 (2), 852, 865
Kurtz SB (abst) 915, 938
Kurtzman NA (abst) 774, 788, 790, 843, 844 (2), 846, 847, 925, 926, 940
Kwaan HC (abst) 889
Kwun K (abst) 218
Kyriakides G (abst) 863

Labeeuw M (abst) . . . 99
Lacombe JL (abst) . . . 94
Lacombe M (abst) . . . 659
Lacy FB: *see* DOBYAN et al . . . 694
Laedrich J (abst) . . . 230, 658
Lagrue G (abst) . . . 657
Laidley L (abst) . . . 88
Lajotte C (abst) . . . 847
Lamanna L (abst) . . . 654
LaMarche MB (abst) . . . 780, 945
Lambre G (abst) . . . 655
Lambrey G (abst) . . . 219, 222, 228, 656
Lameire N (abst) . . . 532, 533
Lamers MC (abst) . . . 213
Lamm LU (abst) . . . 228
Lamperi S (abst) . . . 651
Landini S (abst) . . . 649
Landthaler G (abst) . . . 656
Landwehr DM (abst) . . . 829, 856
Lane K (abst) . . . 951
Laney C (abst) . . . 946
Lang G (abst) . . . 803
Langenbeck U (abst) . . . 231
Langescheid C (abst) . . . 228
Lanier D Jr (abst) . . . 918
Lankester M (abst) . . . 98
Lankisch PG (abst) . . . 237
Lao M (abst) . . . 237
Lao RS (abst) . . . 916
Lapides J (abst) . . . 835
Lappe RW (abst) . . . 825
Laragh JH (abst) . . . 791, 907
Larata E (abst) . . . 654
Largent J (abst) . . . 782
LaRochelle FT (abst) . . . 956 (2)
Lasrich M: *see* MAHER et al . . . 130
Lassiter WE (abst) . . . 850
Lato M (abst) . . . 652
Latos DL (abst) . . . 932
Lattoraga R (abst) . . . 885
LAU K, WOLF C, NUSSBAUM P, WEINER B, DEOREO P, SLATOPOLSKY E, AGUS Z, GOLDFARB S: Differing effects of acid versus neutral phosphate therapy of hypercalciuria . . . 726
Lau K (abst) . . . 851, 861, 943
Laungani G (abst) . . . 949
Laurens NJ (abst) . . . 814
Lauwers E (abst) . . . 656
Lawton WJ (abst) . . . 785
Lazarus JM (abst) . . . 854
Leal-Pinto E (abst) . . . 802
Leb DE (abst) . . . 892
Lebas J (abst) . . . 96
Leber HW (abst) . . . 241
Lebreton P (abst) . . . 244
Lebrun M (abst) . . . 849
Lechene C (abst) . . . 806, 825, 834
Lee CO (abst) . . . 826
Lee CS (abst) . . . 893
Lee DBN (abst) . . . 852, 856
Lee HB (abst) . . . 902
Lee HM (abst) . . . 941
Lee J (abst) . . . 791
Lee JC (abst) . . . 781
Lee RB (abst) . . . 802
Leech SH (abst) . . . 945
Leenen FHH (abst) . . . 236
LeFurgey A: *see* DRATWA et al . . . 695
Leger RT (abst) . . . 887
Legrain M (abst) . . . 96
Leibowitch J (abst) . . . 657
Leier A (abst) . . . 856
Leland OS Jr (abst) . . . 949
Lemann J Jr (abst) . . . 943
LEMIEUX G, VINAY P, BAVEREL G, BRIÈRE R, GOUGOUX A: Relationship between lactate and glutamine metabolism in vitro by the kidney: Differences between dog and rat and importance of alanine synthesis in the dog . . . 451
Lemieux G (abst) . . . 817
Lenhard V (abst) . . . 221
Le Pailleur C (abst) . . . 221
Le Petit JC (abst) . . . 217, 911
Lerman MJ (abst) . . . 889
Leroux-Robert C (abst) . . . 241
Leslie BR (abst) . . . 906
Leslie J (abst) . . . 896
Lespier-Dexter LE (abst) . . . 861, 932
Leveille M (abst) . . . 657
Levere R (abst) . . . 923
Levi J (abst) . . . 772
Leviel F (abst) . . . 658
Levin N (abst) . . . 925
Levin NW (abst) . . . 782 (2), 790
Levine BS (abst) . . . 826, 867
Levine DZ (abst) . . . 835
Levine SD (abst) . . . 823
Levinsky NG (abst) . . . 774, 903
Levitan D (abst) . . . 951
Levitz C (abst) . . . 936
Levy H (abst) . . . 88
Levy L (abst) . . . 798 (2)
Levy M: *see* FELT et al . . . 459
Levy M (abst) . . . 913, 943
Lewin J (abst) . . . 88, 89 (2), 91
Lewin JR (abst) . . . 88 (2)
Lewis EJ (abst) . . . 800 (2), 836, 913, 923
Liang WMM: *see* CHENNAVASIN et al . . . 187
Lianos E (abst) . . . 848, 880, 921
Libertino JA (abst) . . . 949
Liburd EM (abst) . . . 221, 941
Licht JH (abst) . . . 854
Lichtenstein NS (abst) . . . 876
Lieberthal W (abst) . . . 903
Liebross BA (abst) . . . 785
LIEF PD, MUTZ BF, BANK N: Effect of cyclic AMP on hydrogen ion secretion by turtle urinary bladder . . . 103
Lifschitz M (abst) . . . 826, 845, 920
Lifschitz MD (abst) . . . 820
Lim VS (abst) . . . 867
Linares H (abst) . . . 828
Linas SL (abst) . . . 873
LINDNER A, CUTLER RE, GOODMAN WG: Synergism of dopamine plus furosemide in preventing acute renal failure in the dog . . . 158
Lindner A (abst) . . . 785, 892, 915
Lindheimer MD (abst) . . . 871
Lindholm B (abst) . . . 892
Lindsay R (abst) . . . 892

Lindsay RM (abst) 928
Lindsley B (abst) 788
Linkowski P (abst) 242
Linshaw MA (abst) 826, 921
Linton AL (abst) 928
Litkowski L (abst) 948
Little GA (abst) 956
Livingston S (abst) 791
Livio M (abst) 651, 652 (2), 653, 922
Llach F (abst) 775
Lobo PI (abst) 864 (2)
Lockshin M (abst) 926
Locksley R (abst) 918
LOCKWOOD CM: Lymphoma, cryoglobulinemia, and renal disease 522
Lockwood CM (abst) 93, 661
Loep C (abst) 651
Loew H (abst) 224
Logan AG (abst) 794
Loirat C (abst) 656
Lombard WE (abst) 827
Lomnitzer R (abst) 89
London RA (abst) 660, 911
Long DL (abst) 889
Lopez T (abst) 652
López-Novoa JM (abst) 235
López-Trascasa M (abst) 228
Lorentz W (abst) 935
Lornoy W (abst) 97
Losito A (abst) 652
Losuriello V (abst) 654
Lou M (abst) 911
Louis F (abst) 99
Louria DB (abst) 894
Lowenstein J (abst) 794
Lowenstein L (abst) 805
Lowenstein LM (abst) 797
Lucatello S (abst) 649
Lucci MS (abst) 827
Lucia HL (abst) 789
Luciani JC (abst) 97, 657
Lucentini G (abst) 649
Ludwig H (abst) 229
Luft FC (abst) 786, 795, 956
Lühmann H (abst) 218
Luke RG (abst) 824, 825, 852, 879, 933
Lukert B (abst) 851
Lulle J (abst) 658
Lum G (abst) 867
Lund BI (abst) 229
Lund BJ (abst) 229
Lundin AP (abst) 887
Lunne D (abst) 819
Lupi P (abst) 651
Lustig S (abst) 533
Lutton J (abst) 923
Lyon J (abst) 837
Lyons PJ (abst) 901

MAACK T, JOHNSON V, KAU ST, FIGUEIREDO J, SIGULEM D: Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review 251
Macchi E (abst) 649
MACIVER AG, GIDDINGS J, MEPHAM BL: Demonstration of extracellular immunoproteins in formalin-fixed renal biopsy specimens 632
Mackenzie R (abst) 92
Macleod M (abst) 219
Mac-Moune F (abst) 829
Maddox DA (abst) 827
MADIAS NE, ADROGUÉ HJ, HOROWITZ GL, COHEN JJ, SCHWARTZ WB: A redefinition of normal acid-base equilibrium in man: Carbon dioxide tension as a key determinant of normal plasma bicarbonate concentration 612
Madias NE (abst) 808
Madrazo B (abst) 944
Madsen S (abst) 229
Maeda K (abst) 241
Maesaka JK (abst) 918
Maffini M (abst) 651
Maffly RH (abst) 928
Magalhães F (abst) 875 (2)
Maggiore Q (abst) 229, 236, 653
Mahajan S (abst) 883, 893
MAHER JF, HIRSZEL P, LASRICH M: Effects of gastrointestinal hormones on transport by peritoneal dialysis 130
Mahieu P (abst) 95, 839
Mahieu PR (abst) 95, 97, 656
Mahon W (abst) 859
Mailloux L (abst) 932
Maiorca R (abst) 650, 653
Mairano P (abst) 650
Majoor GD (abst) 214
Makker SP (abst) 798, 912, 932
Malek RS: *see* JOHNSON et al 624
Malekzadeh M (abst) 241
Malha F (abst) 94
Malik MC (abst) 229, 658
Mallette LE (abst) 955
Mallick NP (abst) 660, 911
Malluche HH (abst) 827, 828
Malone JD (abst) 856
Man NK (abst) 244
Manaligod J (abst) 940
Mandal AK (abst) 775
Mandel LJ (abst) 804
Mandin H (abst) 856
Manis T (abst) 867, 887, 948
Manisco G (abst) 652
Manz HJ (abst) 883
Maoz B (abst) 888
Marbury TC (abst) 893
Marchesi D (abst) 236, 652 (2), 653, 922
Marchioro TL (abst) 896
Marichez P (abst) 220
Marie P (abst) 222, 656
Marni A (abst) 230
Marr G (abst) 776
Marrink J (abst) 242
Mars DR (abst) 895
Marsden S (abst) 230
Marshall RD (abst) 93
Martens J (abst) 533
Martin D (abst) 832
Martin GR (abst) 801
Martin K (abst) 816, 852

Martin KJ (abst) . . . 867
Martin RR (abst) . . . 955
Martin S (abst) . . . 911
Martinez O (abst) . . . 897
Martinez-Maldonado M (abst) . . . 833, 835, 857
Marty D (abst) . . . 94
Marty-Double C (abst) . . . 97
Marumo F (abst) . . . 241, 828
Marver D (abst) . . . 828
Maskell R (abst) . . . 660
Masselot JP (abst) . . . 230, 657
Massi-Benedetti F (abst) . . . 652
Massry SG (abst) . . . 807, 817 (2), 827, 828, 930, 961
Mastrangelo F (abst) . . . 652
Mathews OP (abst) . . . 876
Mathieu D (abst) . . . 95
Mathieu FJ (abst) . . . 97
Matsui N (abst) . . . 230
Mattammal MB: *see* ZENSER et al . . . 688
Matthaei D (abst) . . . 228, 231
Mauck HP Jr (abst) . . . 792
Mauer SM (abst) . . . 786
Maunsbach AB: *see* CHRISTENSEN and MAUNSBACH 301
Max P (abst) . . . 790
Maxey RW (abst) . . . 884
Maxwell MH (abst) . . . 910
Mayor GH (abst) . . . 779, 780, 830
Mazey R (abst) . . . 816
Mazess RB (abst) . . . 953
Meade R (abst) . . . 776
Meakins J (abst) . . . 943
Mecca G (abst) . . . 236, 651, 652 (2), 653, 896, 922
Medani C (abst) . . . 911
Medlock TR (abst) . . . 876, 888
Medow MS (abst) . . . 829
Meggs LG (abst) . . . 857
Mehandru SK (abst) . . . 933, 937
Mehta P (abst) . . . 788
Mehta S (abst) . . . 231, 946
Meijer S (abst) . . . 214, 240, 532
Melby JB (abst) . . . 873
Menard J (abst) . . . 658
Mench-Hoinowsky A (abst) . . . 231
Mendez G (abst) . . . 941
Mendlewicz J (abst) . . . 242
Mendoza N (abst) . . . 879
Mendrick D (abst) . . . 799
Menniti P (abst) . . . 654
Mepham BL: *see* MACIVER et al . . . 632
Mercier P (abst) . . . 222
Merino MJ (abst) . . . 875
Merkel C (abst) . . . 651
Merle L (abst) . . . 241
Meroni PL (abst) . . . 232
Merrill JP (abst) . . . 911
Messerli FH (abst) . . . 906
Messina M (abst) . . . 650
Metcoff J (abst) . . . 868
Meunier P (abst) . . . 222, 656
Meyer P (abst) . . . 95, 656
Meyer W (abst) . . . 828
Meyer WA (abst) . . . 817, 837
Meyers A (abst) . . . 87
Meyers AM (abst) . . . 87 (2), 88, 89 (2)
Meyrier A (abst) . . . 97, 659 (2)
Michael AF (abst) . . . 801, 808, 810, 851, 931
Michaels AS (abst) . . . 878, 928
Michelis MF (abst) . . . 891, 910
Michels LD (abst) . . . 783, 786
Michielsen P (abst) . . . 533, 659
Midgett RJ (abst) . . . 780
Miele JF: *see* ICHIKAWA et al . . . 137
Miele JF (abst) . . . 854
Migdal SD (abst) . . . 818
Mihatsch MJ (abst) . . . 651
Mikels T (abst) . . . 844
Mikulecky DC (abst) . . . 829
Mikulka WR (abst) . . . 819 (2)
Milani L (abst) . . . 651
Milford EL (abst) . . . 864 (2)
Milgrom M (abst) . . . 213
Milholland H (abst) . . . 884
Millard MM (abst) . . . 787 (2)
Miller J (abst) . . . 775, 863
Miller M (abst) . . . 873
MILLER T, NORTH D: Immunobiologic factors in the pathogenesis of renal infection . . . 665
Miller WC: *see* PURTELL et al . . . 366
Milliez P (abst) . . . 658
Milne CA (abst) . . . 943
Milne FJ (abst) . . . 88 (2), 89 (2)
Milne J (abst) . . . 87
Milutinovich J (abst) . . . 239
Mimran A (abst) . . . 657
Minetti L (abst) . . . 232
Mioli V (abst) . . . 653
Mion C (abst) . . . 239, 899
Mion H (abst) . . . 239, 899
Mioni G (abst) . . . 216, 653
Mirahmadi MK (abst) . . . 893
Mishina T (abst) . . . 828
Misiani R (abst) . . . 653, 922
Misra RP (abst) . . . 862
Mitas JA II (abst) . . . 906, 933, 934
Mitch WE (abst) . . . 894
Mitchell JC (abst) . . . 915
Michell MI (abst) . . . 661
Mock B (abst) . . . 859
Moffat T (abst) . . . 900
MOGENSEN CE, VITTINGHUS E, SØLLING K: Abnormal albumin excretion after two provocative renal tests in diabetes: Physical exercise and lysine injection . . . 385
Mogensen CE (abst) . . . 225
Mohnhaupt A (abst) . . . 217
Mohyuddin F (abst) . . . 816
Mola R (abst) . . . 803 (2), 847 (2)
Molina M (abst) . . . 861
Molnar V (abst) . . . 653
Monaco AP (abst) . . . 949
Moncada S (abst) . . . 244
Monges A (abst) . . . 98
Montalbert C (abst) . . . 941
Montagnino A (abst) . . . 649
Montanaro D (abst) . . . 649
Montcalm A (abst) . . . 807

Monteiro A (abst) 98
Mookerjee BK (abst) 848
Moorthy AV (abst) 914, 953
Moorthy B (abst) 798, 932
Mor J: *see* ROBSON et al 416
Moracchiello M (abst) 649
Moran JK (abst) 882 (2), 888
Morehouse DD (abst) 943
Morelle V (abst) 97
Morel-Maroger L (abst) 86
Morel-Maroger LJ: *see* VERROUST et al 9
Morgan AG (abst) 934
Morgan M (abst) 868
Morley JE (abst) 87
Morris RC Jr (abst) 846, 922
Morris RW (abst) 232
Morrison AB (abst) 800
Morrison AR (abst) 787
Morrison SC (abst) 88
Mortensen L (abst) 950
Moses AM (abst) 935
Moss SH (abst) 935
Mossey R (abst) 932
Moukhtar MS (abst) 219, 655
Mouradian J (abst) 926
Moutoussis G (abst) 882, 883
Mozes MF (abst) 940
Mucia JJ (abst) 873
Mudge GH (abst) 878
Mueller KM (abst) 916
Mueller RP (abst) 916
Mufuka D (abst) 951
MULDOWNEY FP: Diagnostic approach to hypercalciuria 637
Müller-Wiefel DE (abst) 232
Munson KW (abst) 233
Murdock K (abst) 884
Murfin W (abst) 99
Murisasco A (abst) 97
Murphy JF (abst) 861
Murray T (abst) 884
Mushahwar IL (abst) 779
Mussoni L (abst) 896
Mustin M (abst) 94
Muther RS (abst) 231, 917 (3), 934, 946, 947
Mutz BF: *see* LIEF et al 103
Myers BD (abst) 878, 928
Myers S (abst) 848
Myketey N (abst) 820

McAdams AJ: *see* WYATT et al 505
McAnally JF (abst) 933
McCaa RE (abst) 794
McCaffrey C: *see* FELT et al 459
McCarron DA (abst) 231 (2), 917 (2), 946 (2), 947
McCloskey B (abst) 226
McClurkin C (abst) 844
McCluskey RT (abst) 796
McCrorey HL (abst) 857
McDonald F (abst) 893
McDonald FD (abst) 795, 818, 883
McDonald WJ (abst) 792
McFarlane-Anderson N (abst) 846
McGeown MG (abst) 88, 231
McKenna BA (abst) 922
McKenzie JK (abst) 794
McLean CB (abst) 806
McLeish KR (abst) 786
McManus LM (abst) 775
McMaster P (abst) 230
McMorrow RG (abst) 933
McNeil J (abst) 828
McNeil JS (abst) 874
McVicar M (abst) 893, 903

Nagai K (abst) 233
NAGAR D, WATHEN RL: An improved method for renal allograft biopsy 519
Naidich J (abst) 932
Najarian JS (abst) 948
Najem GR (abst) 894
Nakagawa S (abst) 230, 894
Nakane H (abst) 658
Nakane Y (abst) 658
Narins RG (abst) 776
Nascimento L (abst) 857
Nash DA Jr (abst) 874
Navar LG (abst) 806
Neale TJ (abst) 783, 799
Nebiolo PE (abst) 652
Needham-Walker C (abst) 881
Needleman P (abst) 787
Neels HM: *see* VAN ACKER et al 196
Neilson EG (abst) 799 (2)
Nelson JD (abst) 914
Nemati C (abst) 905
Nemerson Y (abst) 870
NEUHAUS OW, LERSETH DS: Dietary control of the renal reabsorption and excretion of α_{2u}-globulin 409
Neuhauser M (abst) 955
Neusy AJ (abst) 794
Neviackas J (abst) 918
Nevins TE (abst) 931
Newman B (abst) 89
Newman WJ (abst) 855
Niarchos AP (abst) 907
Nicastri AD (abst) 936
Nicholas JA (abst) 910
Nicholas ML (abst) 233
Nicholson GD (abst) 934
Nickel AE (abst) 820
Nicot G (abst) 241
Nidus BD (abst) 894
Niedermayer W (abst) 242
Nielsen B (abst) 222
Nielsen IL (abst) 222
Nielubowicz J (abst) 237
Nightingale SD (abst) 934
Ninin DT (abst) 88
Nissenson AR (abst) 785
Nivez MP (abst) 847
Nixon J (abst) 233
Noble B (abst) 213, 799
Noel LH (abst) 657
Nolen P (abst) 99
Nolph K: *see* RUBIN et al 619

Nolph K (abst) . . . 780, 892
Noordewier B (abst) . . . 830
Nord E (abst) . . . 234
Nordquist J (abst) . . . 775
Norman AW (abst) . . . 828, 920
Norman DJ (abst) . . . 863
Norman ME (abst) . . . 906
Norris S (abst) . . . 863
North D: *see* MILLER and NORTH . . . 665
Nosadrini R (abst) . . . 224
Notman DD (abst) . . . 935
Novak R (abst) . . . 914
Novick AC (abst) . . . 908
Novogrodsky A (abst) . . . 240, 864 (2), 913, 949
Noyes W (abst) . . . 952
Nussbaum P: *see* LAU et al . . . 726

Obertop H (abst) . . . 234
Obiedzinski G (abst) . . . 913, 927
O'Connor DT (abst) 779, 904 (2), 907 (2), 909 (2), 922, 924, 934
O'Donnell M (abst) . . . 813
Oegema TR (abst) . . . 808
Oei HY (abst) . . . 531
O'Fallon WM: *see* JOHNSON et al . . . 624
Offerman G (abst) . . . 218
Ogden DA (abst) . . . 895
Ogilvie R (abst) . . . 954
Oh MS (abst) . . . 895, 921
Ohno J (abst) . . . 785
Ointer GG (abst) . . . 810, 844
Oken DE (abst) . . . 773, 829, 856, 877
Ølgaard K (abst) . . . 224, 229
Oliveira A (abst) . . . 875
Oliver DO (abst) . . . 226
Oliver JA (abst) . . . 830
Oliver W (abst) . . . 862
Olivero J (abst) . . . 881 (2)
Olmer M (abst) . . . 98, 222
Olsen LS (abst) . . . 846
Olshan A (abst) . . . 901
Olshan AR (abst) . . . 907, 922
Olson JL (abst) . . . 787, 857
Olson K (abst) . . . 936
Olson P (abst) . . . 805, 836
Olsson PJ (abst) . . . 895
Omachi R (abst) . . . 842, 927
O'Morchoe CCC: *see* ALBERTINE and O'MORCHOE . . . 470
O'Morchoe CCC (abst) . . . 830
O'Morchoe PJ (abst) . . . 830
OOI BS, WEISS MA, HAMOUI T: Effect of renal vein constriction on the localization of immune complexes in the kidney . . . 681
Ooi BS (abst) . . . 878, 912, 930
Ooi YM (abst) . . . 912
Oparil S: *see* CARONE et al . . . 271
Oparil S (abst) . . . 831
Opava-Stitzer S (abst) . . . 833
Opelz G (abst) . . . 948
O'Reilly JP (abst) . . . 781
Oreopoulos D (abst) . . . 892
Oreopoulos DG (abst) . . . 234 (2), 780, 954
Oriol R (abst) . . . 96
Orloff J (abst) . . . 806
Orlowski T (abst) . . . 237
Ørskov H (abst) . . . 224
Orsoni G (abst) . . . 219
Ortega M (abst) . . . 948
Osborn JL (abst) . . . 795
Osborne D (abst) . . . 866
Oscar G (abst) . . . 226
Osgood RW (abst) . . . 771, 781
Ota K (abst) . . . 235
Otsubo O (abst) . . . 235
Ott C (abst) . . . 842
Ou SL (abst) . . . 781, 858
Overlack A (abst) . . . 871
OYEDIRAN ABOO: Renal disease due to schistosomiasis of the lower urinary tract . . . 15
Ozawa T (abst) . . . 859

Pabico RC (abst) . . . 922
Pacitti A (abst) . . . 652
Packham DA (abst) . . . 233
Pagel M (abst) . . . 233
Paillard M (abst) . . . 658
Palcoux JB (abst) . . . 96
Panzetta G (abst) . . . 653
PARBTANI A, CAMERON JS: Experimental nephritis associated with plasmodium infection in mice . . . 53
Pardo SJ (abst) . . . 934
Pardo V (abst) . . . 778, 935
Park CS (abst) . . . 831
Park R (abst) . . . 918
Parker D (abst) . . . 775
Parker RA (abst) . . . 773, 775
Parker T (abst) . . . 946
Parker TF (abst) . . . 889
Parkhill T (abst) . . . 795
Parkinson IS (abst) . . . 230
Parkman R (abst) . . . 797
Parlongo S (abst) . . . 653
Parlongo T (abst) . . . 229
Parsons V (abst) . . . 233, 243
Pascoe MD (abst) . . . 90
Pascoe N(abst) . . . 787
Pascual J (abst) . . . 861
Pasternak FL (abst) . . . 910
Pastore (abst) . . . 654
PASTORIZA-MUNOZ E, BOWMAN RL, KALOYANIDES GJ: Renal tubular transport of gentamicin in the rat . . . 440
Pastoriza E (abst) . . . 831
Patak RV (abst) . . . 776
Paton A[illegible] (abst) . . . 876, 888
Patterson MJ (abst) . . . 779, 780
Patton SR (abst) . . . 935
Paty J (abst) . . . 899
Paul LC (abst) . . . 235, 864 (2)
Pauli BU (abst) . . . 836
Paulus HE (abst) . . . 910
Pauw FH (abst) . . . 90
Pazderka F (abst) . . . 945
Pazderka V (abst) . . . 221
Pazmiño PA (abst) . . . 954
Pead L (abst) . . . 660
Pearson JA (abst) . . . 780
Peces R (abst) . . . 235

Pederson J (abst) . . . 868
Pellascio ML (abst) . . . 777
Pellegrino S (abst) . . . 223
Pellet H (abst) . . . 658
Pellet M (abst) . . . 98, 654
Pelletier V: *see* STERNBERG et al . . . 329
Penico PE (abst) . . . 937
Pennell JP (abst) . . . 787 (2)
Pennisi A (abst) . . . 241
Peress N (abst) . . . 912
Perez GO (abst) . . . 935
Perkins F (abst) . . . 822
Perrot H (abst) . . . 229
Perry MC (abst) . . . 777
Persijn GG (abst) . . . 225
Persijn JP (abst) . . . 937
Pertschuk L (abst) . . . 936
Pesce AJ: *see* CLYNE et al . . . 345
Pesce AJ: *see* PURTELL et al . . . 366
Pesce AJ (abst) . . . 920
Peters DK (abst) . . . 92, 93, 661
Peters P (abst) . . . 943, 946
Petersen J (abst) . . . 235
Peterson DR: *see* CARONE et al . . . 271
Peterson DR (abst) . . . 831
Peterson NR (abst) . . . 934
Peterson O (abst) . . . 848
Peterson OW (abst) . . . 841
Petrulis AS (abst) . . . 858
Pettinger W (abst) . . . 889
Phillips SM (abst) . . . 799 (2)
Phillips TM (abst) . . . 950
Picaud D (abst) . . . 99
Piccoli A (abst) . . . 649
Piccoli C (abst) . . . 650
Piccoli G (abst) . . . 219
Pickering J (abst) . . . 895
Picotti (abst) . . . 651
Picotti GB (abst) . . . 650, 654
Pierce JV (abst) . . . 785
Pierides AM (abst) . . . 935
Piering WF (abst) . . . 943
Pilia PA (abst) . . . 788
Pils P (abst) . . . 227 (3), 238
Pimstone B (abst) . . . 91
Pinching AJ (abst) . . . 661
Pinckard RN (abst) . . . 775
Pinggera WF (abst) . . . 224
Pinto J (abst) . . . 830
Piou E (abst) . . . 933
Pirani CL (abst) . . . 789, 946
Pircher W (abst) . . . 916
Pirsch G (abst) . . . 864 (2)
Pirson Y (abst) . . . 98
Pisano JJ (abst) . . . 785
Plamp CE (abst) . . . 775
Plant S (abst) . . . 947
Plant SB (abst) . . . 231, 946
Plaut ME (abst) . . . 879
Plavljanic D (abst) . . . 653
Pletka P (abst) . . . 891
Ploth DW (abst) . . . 831
Plunkett WC (abst) . . . 817
Poessé MA (abst) . . . 533
Poggi A (abst) . . . 229, 236, 653
Pohl MA (abst) . . . 908
Pointet P (abst) . . . 99
Poler SM (abst) . . . 858
Poletti E (abst) . . . 652
Pollak VE: *see* HONG et al . . . 167
Pollak VE: *see* PURTELL et al . . . 366
Pollak VE (abst) . . . 878, 930, 931
Pomero P (abst) . . . 240
Ponticelli C (abst) . . . 218
Popli S (abst) . . . 889, 895
Port FK: *see* BERNICK et al . . . 491
Port FK: *see* SWARTZ and PORT . . . 513
Port FK (abst) . . . 896, 949
Portale AA (abst) . . . 922
Porter GA (abst) . . . 773, 775, 791
Porush JG (abst) . . . 851
Potter D (abst) . . . 887, 945, 948
Poulos PM (abst) . . . 89
Pourrat JP (abst) . . . 658
Pourrat O (abst) . . . 99
Pozet N (abst) . . . 98
Prasad A (abst) . . . 893
Prasad AS (abst) . . . 818
Prasad J (abst) . . . 832
Prati RC (abst) . . . 889
Prenen JAC (abst) . . . 236
Prenter A (abst) . . . 241
Prestidge H (abst) . . . 779
Preston A (abst) . . . 822
Preston RA (abst) . . . 907
Preston S (abst) . . . 920
Price C (abst) . . . 879
Primack WA (abst) . . . 916
Prins EJL (abst) . . . 236, 532, 904
Privette M (abst) . . . 919
Prosper G (abst) . . . 897
Proud D (abst) . . . 785
Prowant B: *see* RUBIN et al . . . 619
Pucacco LR (abst) . . . 811, 827
Pujo JM (abst) . . . 94
Pullman TN: *see* CARONE et al . . . 271
Pumper M (abst) . . . 796
Pumphrey RSH (abst) . . . 660
PURTELL JN, PESCE AJ, CLYNE DH, MILLER WC, POLLAK VE: Isoelectric point of albumin: Effect on renal handling of albumin . . . 366
Puschett JB (abst) . . . 832, 834
Pusineri F (abst) . . . 896
Pussell B (abst) . . . 92
Pussell BA (abst) . . . 661
Puylaert CBAJ (abst) . . . 531

Quadracci L (abst) . . . 924
Quamme GA (abst) . . . 832, 845 (2)
Quarello F (abst) . . . 219, 650
Querido D (abst) . . . 90
Quintanilla A (abst) . . . 903, 922, 951

Rabetoy GM (abst) . . . 933
Rabinowitz L (abst) . . . 833
Rabito CA (abst) . . . 833

RABKIN R, UNTERHALTER SA, DUCKWORTH WC: Effect of prolonged uremia on insulin metabolism by isolated liver and muscle 433
Rabkin R (abst) 816, 533
Rabson AR (abst) 89
Radaelli L (abst) 650
Raij L (abst) 784, 800
Raja R (abst) 897
Rajudin M (abst) 884
Ralston AJ (abst) 216
Ramos E (abst) 896
Rampal M (abst) 222
Rankin LI (abst) 786, 795
Rannels DE (abst) 866
Rao D (abst) 897
Rao KV (abst) 936
Rao TKS (abst) 884, 936
Rapola J (abst) 939
Raska K Jr (abst) 800
Raskova J (abst) 800
Rasmussen H (abst) 805
Rattazzi T (abst) 233, 896
Rattazzi LC (abst) 896
Rault R (abst) 892
Rauterberg EW (abst) 913
Ravazzani C (abst) 654
Raw SM: *see* CLARKSON et al 710
Rayfield E (abst) 222
Rector FC Jr (abst) 809 (2), 810, 827
Reddish MA (abst) 942
Rees AJ (abst) 661
Reese AH (abst) 810
Refetoff S (abst) 867
Reif M (abst) 802
Reimold EW (abst) 936
Reineck HJ (abst) 771
Reinking LN (abst) 830
Reis P (abst) 87
Reisin E (abst) 794
Reisine T (abst) 914
Reiss E (abst) 787
Remuzzi G (abst) 236, 651, 652, (2), 653, 896, 922
Renault L (abst) 95
Rennert O (abst) 868
Rennke HG (abst) 776, 787, 857
Reubi F (abst) 98
Richard C: *see* FELT et al 459
Richard GA (abst) 952
Richard-Lenoble D: *see* VERROUST et al 9
Richards CJ (abst) 866
Richards P (abst) 938
Richardson J (abst) 897
Richardson MC (abst) 899
Richardson R (abst) 817
Richardson RMA (abst) 860
Rieselbach RE (abst) 890
Riggio RR (abst) 237, 864 (2)
Rigney JH (abst) 779
Rigolosi R (abst) 880
Rigosa C (abst) 653
Rinaudo JB (abst) 97
Rinner SE (abst) 889
Ritchie JL (abst) 915
Ritchie S (abst) 928
Ritz E: *see* BOMMER et al 722
Ritz E (abst) 218
Rivolta E (abst) 649
Rizzelli S (abst) 652
Robaudo C (abst) 651
Roberts C (abst) 952
Roberts JL (abst) 800 (2), 913, 923
Robertson CR: *see* JAMISON and ROBERTSON 537
Robertson G (abst) 873
Robertson GL: *see* ROWE et al 729
Robertson GL (abst) 956
Robertson JS (abst) 832, 834
Robinette JB (abst) 850
Robinson B (abst) 241
Robinson JA (abst) 889
Robinson MF (abst) 800
Robinson RR (abst) 855
ROBSON AM, MOR J, ROOT ER, JAGER BV, SHANKEL SW, INGELFINGER JR, KIENSTRA RA, BRICKER NS: Mechanism of proteinuria in nonglomerular renal disease 416
Robson AM: *see* ROSENBAUM et al 179
Robson AM (abst) 939
Robson V (abst) 661
Robson WLM (abst) 860
Roccatagliata G (abst) 651
Roche H: *see* ANDRADE and ROCHA 23
Rocha P (abst) 220
Rodgers ML (abst) 856
Rodrigues M (abst) 875
Rodriguez E (abst) 782
Rodriguez HJ (abst) 802
Roelcke D (abst) 221
Roels L (abst) 659
Rogers D (abst) 877
Rohrbach R (abst) 217
Roinel N (abst) 873 (2)
Roland J (abst) 659
Rolla A (abst) 875
Roman RJ (abst) 834
Romanski R (abst) 924
Romeo G (abst) 653
Römer W (abst) 221
Romero JC (abst) 805, 836
Romito S (abst) 654
Romoff MS (abst) 951
Roncari DAK (abst) 954
Ronzoni L (abst) 651
Roos JC (abst) 531, 660
Root ER: *see* ROBSON et al 416
Rosa R (abst) 905
Rosa RM (abst) 874
Rosansky SJ (abst) 936
Rosati G (abst) 223
Roscoe J (abst) 928
Rose BD (abst) 814
Roseman M (abst) 924
Rosen S (abst) 836
ROSENBAUM RW, HRUSKA KA, ANDERSON C, ROBSON AM, SLATOPOLSKY E, KLAHR S: Inulin: An inadequate marker of glomerular filtration rate in kidney donors and transplant recipients 179

Rosenbaum JL (abst) 897
Rosenbaum R (abst) 947 (2)
Rosenfeld J (abst) 234
Rosenkrantz H (abst) 906
ROSENMANN E, BOSS JH: Tissue antigens in normal and pathologic urine samples: A review 337
Rosenquist R (abst) 951
Roser BJ (abst) 863
Rosier JGMC (abst) 214
Roskes S (abst) 910
Ross M (abst) 775
Rossetti R (abst) 891
Rostan A (abst) 95
ROSTAND SG, GRETES JC, KIRK KA, RUTSKY EA, ANDREOLI TE: Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis 600
Rostand SG (abst) 834
Rother K (abst) 913
Rottembourg J (abst) 98
Rouse D (abst) 840
Rovinetti C (abst) 653
ROWE JW, SHELTON RL, HELDERMAN JH, VESTAL RE, ROBERTSON GL: Influence of the emetic reflex on vasopressin-release in man 729
Rowińska D (abst) 237
Rowiński W (abst) 237
Roxe D (abst) 947
Roy C (abst) 804 (2), 822
Roy D (abst) 834
Roy R (abst) 831
Roy S III (abst) 937
Rubin AL (abst) 237, 240, 864 (4), 913, 949
RUBIN J, NOLPH K, ARFANIA D, BROWN P, PROWANT B: Follow-up of peritoneal clearances in patients undergoing continuous ambulatory peritoneal dialysis 619
Rubin J (abst) 780, 897
Rubinstein H (abst) 846
Rubler S (abst) 890
Ruddy MC (abst) 913
Ruehland D (abst) 916 (2)
Ruinen L (abst) 242
Rumpf KW (abst) 237
Rurale D (abst) 218
Russell RGG (abst) 226
Russell RP (abst) 905, 907, 909 (2), 910 (2)
Russo D: *see* USBERTI et al 546
Rutecki GW (abst) 850
Rutledge P (abst) 859
Rutsky EA: *see* ROSTAND et al 600

Sabatier JC (abst) 217
Sabatini S (abst) 788, 803 (2), 868, 846
Sabnis SG (abst) 925
Sabtier JC (abst) 911
Sack EM (abst) 844
Sackin H (abst) 835
Sadler JH (abst) 896, 948
Safirstein R (abst) 775
Saggioro A (abst) 649
Saghafi D (abst) 937
Saingra S (abst) 97
Saito H (abst) 777, 909
Sakai T (abst) 828
Sakamoto R (abst) 894
Salant DJ (abst) 797, 801 (2)
Salcedo JR (abst) 897, 937
Salik JM (abst) 890
Salvatierra O (abst) 242, 940, 948
Samuels S (abst) 930
Sancho J (abst) 228
Sands JM (abst) 840
Sandstead H (abst) 868
Sanfelippo M (abst) 779, 868, 898
Santhanam S (abst) 947
Santiago J (abst) 947 (2)
Sapir DG (abst) 894
Saraniti AJ (abst) 910
Sargent J (abst) 887
Sargent JA (abst) 951
Sasaoka S (abst) 894
Sasaoka T (abst) 230
Sasdelli M (abst) 653
Sasso E (abst) 907
Sastrasinh S (abst) 835
Sastry S (abst) 782
Saubermann AJ (abst) 805
Savin V (abst) 772, 788
Savin VJ (abst) 776
Sawyer M (abst) 877
Scarpelli PT (abst) 654
Scetbon V (abst) 659
Schacht RG (abst) 913, 927, 929
Schaller JG (abst) 938
Schambelan M (abst) 854, 858
Schanzer H (abst) 218
Schardijn GHC (abst) 937
Schärer K (abst) 221, 232
Scharpe SL: *see* VAN ACKER et al 196
Schartl M (abst) 238
Schauder P (abst) 231
Scheiber SC (abst) 914
Scheiner E (abst) 898
Scheinman JI (abst) 801
Scheler F (abst) 228, 231, 237
Schena FP (abst) 654
Schenck RD (abst) 228
Schentag JJ (abst) 879
Schernthaner G (abst) 237
Schey HM (abst) 930
Schieppati A (abst) 651
Schiffer MS (abst) 851
Schillinger FG (abst) 898
Schilthuis MS (abst) 214
Schindhelm K (abst) 238
Schlatter E (abst) 238
Schleifer CR (abst) 908
Schlondorff D (abst) 858, 874
Schmidt M (abst) 96
Schmidt P (abst) 227 (3), 238
SCHMIDT RW, DANOVITCH GM: Glucose reabsorption in experimental renal insufficiency: Effects of proportional reduction of sodium intake . . . 590
Schmidt-Nielsen B (abst) 830
Schneeberger EE (abst) 796

Schneider B (abst) . . . 908
Schneider H (abst) . . . 238
Schnermann J (abst) . . . 808, 835
Schoenfeld PY (abst) . . . 898
Schohn DC (abst) . . . 898
Schomacher PH (abst) . . . 916
Schon DA (abst) . . . 819
Schoolwerth AC (abst) . . . 866
Schor N (abst) . . . 776, 835
Schreiber MJ (abst) . . . 908
Schreiner GE (abst) . . . 933, 950
Schreve RH (abst) . . . 234
Schrier N (abst) . . . 789
Schrier R (abst) . . . 957
Schrier RW (abst) . . . 849, 857, 869
Schroeder ET (abst) . . . 873
Schrogie JJ (abst) . . . 802
Schryver S (abst) . . . 805, 836
Schultz DR (abst) . . . 935
Schurek HJ: *see* STOLTE et al . . . 377
Schurek HJ (abst) . . . 238
Schurig R (abst) . . . 217, 238
Schütterle G (abst) . . . 241
Schwartz F (abst) . . . 868
Schwartz GJ (abst) . . . 836
Schwartz IL (abst) . . . 870
Schwartz JH (abst) . . . 836, 869
Schwartz MJ (abst) . . . 828, 874
SCHWARTZ MM, KARNOVSKY MJ, VENKATACHALAM MA: Regional membrane specialization in the limbs of Henle's loops as seen by freeze-fracture electron microscopy . . . 577
Schwartz MM (abst) . . . 836
Schwartz WB: *see* MADIAS et al . . . 612
Schweiger C (abst) . . . 654
Sciacca RR (abst) . . . 830
Scott D (abst) . . . 240
Scribner BH (abst) . . . 233, 239, 924
Scriver CR (abst) . . . 840
Scullica L (abst) . . . 653
Sealey JE (abst) . . . 791
Sebastian A (abst) . . . 821 (2), 854 (3), 858
Sebban M (abst) . . . 96
Sebert JL (abst) . . . 222, 656
Seedat YK (abst) . . . 90 (2), 91
Seegers A (abst) . . . 228
Seely JF (abst) . . . 834
Segel DP (abst) . . . 924, 927
Segoloni C (abst) . . . 650
Segoloni G (abst) . . . 219
Segoloni S (abst) . . . 650
Sehy JT (abst) . . . 925
Seidel CL (abst) . . . 860
Seiler A (abst) . . . 98
Seiler MW: *see* HOYER and SEILER . . . 279
Seiwell R: *see* CHENNAVASIN et al . . . 187
Seiwell R (abst) . . . 919
Selden R (abst) . . . 893
Seldin DW (abst) . . . 811
Seller A (abst) . . . 659
Sellers BB Jr (abst) . . . 837
Senekjian HO: *see* KNIGHT et al . . . 572
Senekjian HO (abst) . . . 824, 837, 843
Seo H (abst) . . . 867
Serros E (abst) . . . 813
Serros ER (abst) . . . 785
Severin M (abst) . . . 218
Shah SV (abst) . . . 781, 788, 855, 858
Shaldon S (abst) . . . 239, 899
Shalhoub RJ (abst) . . . 880
Shankel E (abst) . . . 911
Shankel S (abst) . . . 951
Shankel SW: *see* ROBSON et al . . . 416
Shannon WA (abst) . . . 865
Shapiro B (abst) . . . 91
Shapiro FL (abst) . . . 886, 936
Shareghi GR (abst) . . . 837
Sharma B (abst) . . . 885
Sharon Z (abst) . . . 800, 836
Shaw JO (abst) . . . 848
Shaw K (abst) . . . 795
Shearer TP (abst) . . . 783
Shearn MA (abst) . . . 931
Shelton RL: *see* ROWE et al . . . 729
Shen YL (abst) . . . 896, 948
Shenouda AN (abst) . . . 899
Sheppard M (abst) . . . 91
Sheps SG (abst) . . . 908
Shere J (abst) . . . 900
Sherman D (abst) . . . 828
Sherman R (abst) . . . 926
Sherrard DJ (abst) . . . 888, 892
Shier DN (abst) . . . 873
Shimada H (abst) . . . 828
Shimamura T (abst) . . . 789
Shimizu A (abst) . . . 899
Shinaberger J (abst) . . . 898
Shindo T (abst) . . . 838
Shirani KZ (abst) . . . 948
Shirani KZ (abst) . . . 949
Shivji S (abst) . . . 945
Shoji T (abst) . . . 894
Shuster A (abst) . . . 771
Sicard G (abst) . . . 847, 852, 886
Siddiqui F (abst) . . . 947
Sieberth HG (abst) . . . 239
Siedlecki M (abst) . . . 899
Siegel N (abst) . . . 930
Siegel NJ (abst) . . . 776
Siegel SR (abst) . . . 795
Sienknecht CW (abst) . . . 899
Sigal-Saglier M (abst) . . . 221
Sigler MH (abst) . . . 908
Sigulem D: *see* MAACK et al . . . 251
Sillis V (abst) . . . 852, 856
Silva F (abst) . . . 956
Silva FG (abst) . . . 789
Silver MJ (abst) . . . 236
Silverman M (abst) . . . 859
Silverstein CE (abst) . . . 904
Silverstein RL (abst) . . . 889
Simada Y (abst) . . . 235
Simon M (abst) . . . 227
Simon P (abst) . . . 659
Simone JN (abst) . . . 843
Simmons CF Jr (abst) . . . 776, 778, 862

Simmons RL (abst) . . . 948
Simpson DP (abst) . . . 953
Simpson JG (abst) . . . 235
Simpson NB (abst) . . . 239
Simpson S (abst) . . . 92
Singer FR (abst) . . . 827
Singer I (abst) . . . 814, 870
Singer L (abst) . . . 96
Sirkka M (abst) . . . 223
Sirota J (abst) . . . 833
Sirota R (abst) . . . 901
Sirota RA (abst) . . . 876
Sisca S (abst) . . . 653
Sisson S (abst) . . . 920
Sitprija V: *see* BOONPUCKNAVIG and SITPRIJA . . . 44
Skowsky R (abst) . . . 904 (2)
Slatopolsky E: *see* LAU et al . . . 736
Slatopolsky E: *see* ROSENBAUM et al . . . 179
Slatopolsky E (abst) . . . 816, 852, 867, 924, 947 (2)
Slavicek JM (abst) . . . 777
Slegers JFG (abst) . . . 532
Slia R (abst) . . . 658
Slooff MJH (abst) . . . 240
Smeby L (abst) . . . 225
Smith AJ Jr (abst) . . . 916
Smith FW (abst) . . . 219
Smith IJ (abst) . . . 812
Smith JA (abst) . . . 782
Smith MD: *see* VERROUST et al . . . 9
Smith MJ (abst) . . . 793
Smith QT (abst) . . . 915
Snider TH (abst) . . . 920
Snyder J: *see* WYATT et al . . . 505
Sobel A (abst) . . . 657
Sobel AT (abst) . . . 655
Soberon LM (abst) . . . 954
Sodhi B (abst) . . . 774
Soeda N (abst) . . . 785
Soffer O (abst) . . . 923
Solangi K (abst) . . . 923
Sole M (abst) . . . 861
Solez K (abst) . . . 777, 859, 778
Sølling K: *see* MOGENSEN et al . . . 385
Solomon R (abst) . . . 923
Sombolos C (abst) . . . 902
SOMERVILLE PJ, KAYE M: Evidence that resistance to the calcemic action of parathyroid hormone in rats with acute uremia is caused by phosphate retention . . . 552
Sommer BG (abst) . . . 948
Sonnenberg H (abst) . . . 837 (2), 838
Sørensen OH (abst) . . . 229
Sorkin MI (abst) . . . 777
Soroka K (abst) . . . 849
Sosin AE (abst) . . . 779, 887
Sossler C (abst) . . . 655
Southern P (abst) . . . 849
Sova-Schulz K (abst) . . . 907, 909
Spangler W (abst) . . . 771
Spector D (abst) . . . 899
Spencer C (abst) . . . 864 (2)
Spiegelberg HL (abst) . . . 801
Spielman WS (abst) . . . 838 (2)
Spina GP (abst) . . . 651
Spinowitz B (abst) . . . 927
Spinowitz BS (abst) . . . 913
Spitalewitz S (abst) . . . 851
Spitzer R (abst) . . . 784
Splendiani G (abst) . . . 740
Spolter D (abst) . . . 774
Spona J (abst) . . . 237
Spreiter SC (abst) . . . 777
Spring KR (abst) . . . 838
Sprinkle FM (abst) . . . 856
Sproviero R (abst) . . . 654
Sraer J (abst) . . . 839, 847
Sraer JD (abst) . . . 97
Stahl R (abst) . . . 791
Stamoutsos BA (abst) . . . 871
Stanley C (abst) . . . 906
Stanton BA (abst) . . . 839
Stapleton FB (abst) . . . 938
Starkman M (abst) . . . 839
Starrs J (abst) . . . 938
Stathakis H (abst) . . . 902
Steele JM Jr (abst) . . . 794
Steele K (abst) . . . 797
Steele RE (abst) . . . 836
Steele TH (abst) . . . 859
Steffes MW (abst) . . . 786
Stefoni S (abst) . . . 219
Steg A (abst) . . . 659
Stein JH (abst) . . . 771, 775, 781, 820
Stein R (abst) . . . 883
Stein RM (abst) . . . 855
Steinberg SM (abst) . . . 933
Steinhausen D (abst) . . . 224
Steinzel KH (abst) . . . 237, 240
Stenzel KH (abst) . . . 864 (4), 913, 949
Stephen RL (abst) . . . 226
Stephens MK (abst) . . . 889
Stephenson JL (abst) . . . 836
Steplock DA: *see* KNIGHT et al . . . 572
Stern P (abst) . . . 956 (2)
STERNBERG M, DE GRANDPRÉ P, PELLETIER V, CARTER M: Excretion and synthesis of basement membrane disaccharide units in Masugi nephrits . . . 329
Sternberg M (abst) . . . 99
Sterns RH (abst) . . . 953
Sterzel RB (abst) . . . 789
Stewart R (abst) . . . 771
Steyart J (abst) . . . 98
Still WJ (abst) . . . 856
Stillmant MM (abst) . . . 797, 801 (2)
Stinebaugh B (abst) . . . 817, 837
Stinebaugh BJ (abst) . . . 860
Stöckmann F (abst) . . . 237
Stoff JS (abst) . . . 874
Stokes JB (abst) . . . 839
STOLTE H, SCHUREK HJ, ALT JM: Glomerular albumin filtration: A comparison of micropuncture studies in the isolated perfused rat kidney with in vivo experimental conditions . . . 377
Stolte H (abst) . . . 238
Stone H (abst) . . . 868

Stone RA (abst) 904 (2), 907 (2), 919 (2), 922, 924
Stone WJ (abst) 900
Stout RL (abst) 778
Stout-Zonneveld AAM (abst) 937
Strang KD (abst) 533
Stratta P (abst) 650
STRAUS W: Renal reabsorption and excretion of horseradish peroxidase 404
Streicher E (abst) 238
Striker G (abst) 924, 938
Strom JA (abst) 808
Strom TB (abst) 944
Strong CG (abst) 954
Stropes LL (abst) 956
Struyvenberg A (abst) 225
Stuart E (abst) 844
Stubenbord WD (abst) 237
Stubenbord WT (abst) 945
Stummvoll HK (abst) 224, 237
Stummvoll K (abst) 229
Sturgill BC (abst) 848
Suarez DH (abst) 906
Suarez G (abst) 933
Subbarayudu K (abst) 847
Suenaga M (abst) 230
Sugarman A (abst) 855
Suki WN (abst) 840, 879
Sullivan JF (abst) 864 (2), 906
Surian M (abst) 216, 232, 649, 650
Susin M (abst) 932
Suthanthiran M (abst) 237, 240, 864 (4), 949
Sutherland DER (abst) 948
Sutton DMC (abst) 941
Sutton J (abst) 927
Sutton JM (abst) 854, 858
Suzuki Y (abst) 941
Swain RP (abst) 788
Swainson CP (abst) 93
Swamy AP (abst) 900
Swanson J (abst) 806
Swartz C (abst) 793, 938
SWARTZ RD, PORT FK: Preventing hemorrhage in high-risk hemodialysis: Regional versus low-dose heparin 513
Swartz RD (abst) 949, 954
Swenson RS (abst) 777
Swerdlin AR (abst) 906
Sy W (abst) 916
Sylk DB (abst) 832, 834
Szatalowicz V (abst) 957
Szmidt J (abst) 237
Szwed JJ (abst) 859

Taboury J (abst) 659
Taher S (abst) 795
Taillandier E (abst) 659
Takacs FJ (abst) 949
Takahashi I (abst) 235
Takamiya H (abst) 217
Takeuchi J (abst) 230
Tam SC (abst) 817, 860
Tang ACM (abst) 777
Tannen R (abst) 835
Tannen RL (abst) 840
Tanquerel T (abst) 659
Tapia L (abst) 864 (2)
Tarantino A (abst) 651
Taylor A (abst) 807, 814, 826
Taylor B (abst) 919
Taylor CM (abst) 226
Taylor K: *see* KNIGHT et al 572
Tedesco A (abst) 654
Tegtmeyer E (abst) 866
Tegzess AM (abst) 240
Teitelbaum SL (abst) 856, 902, 924
Teixeira RB (abst) 778
Telfer N (abst) 220
Tenenhouse HS (abst) 840
Tepper E (abst) 918
Terao N (abst) 840
Terasaki P (abst) 948
Teresi LM (abst) 840
Terreros D (abst) 788
Thea A (abst) 652
Thebaud HE (abst) 659
Thien T (abst) 214, 532
Thind IS (abst) 894
Thomas E (abst) 659
Thomas J (abst) 659
Thompson P (abst) 233
Thompson RE: *see* CLYNE et al 345
Thomson D (abst) 93, 771
Thomson NM (abst) 240, 880
Thomson PD (abst) 88
TIGGELER RGWL, HULME B, WIJDEVELD PGAB: Effect of indomethacin on glomerular permeability in the nephrotic syndrome 312
Tiggeler RGWL (abst) 214
Tina L (abst) 911
Tincani A (abst) 232
Tisher CC: *see* DRATWA et al 695
Tizianello A (abst) 651
Tobian L (abst) 796
Tobin M (abst) 921
Toledo-Pereyra (abst) 944
Tolkoff-Rubin (abst) 887
Tomford RC (abst) 789
Top Dvd (abst) 534
Torelli J (abst) 855
Torikai S (abst) 824, 841 (2), 865
Torres VE (abst) 938
Torretti J (abst) 796
Touchard G (abst) 99
Toulet R (abst) 659
Touraine JL (abst) 229, 658
Toussaint C (abst) 94
Traeger J (abst) 98, 229
Trasforini D (abst) 651
Trautmann M (abst) 228
Trebbin W (abst) 923
Treffot MJ (abst) 98
Treves S (abst) 877
Trigg D (abst) 832
Trimble ME (abst) 935
Trinh MM (abst) 847

Trizna W (abst) 823
Trizna W (abst) 813
Trombert JC (abst) 94
Troy JL (abst) 783, 822, 835
Tsai HC (abst) 922
Tschöpe W: *see* BOMMER et al 722
Tsukamoto Y (abst) 241
Tu WH (abst) 927, 939
Tucker BJ (abst) 841, 848
Tucker RM (abst) 908, 929
Tucker T (abst) 900
Tuma SN (abst) 860, 955
Turini GA (abst) 243
Turnbull AD (abst) 898
Turner MW: *see* HUTTUNEN et al 322

Uittenbogaart CH (abst) 241
Uldall PR (abst) 941
Uniyal B (abst) 899
Unterhalter SA: *see* RABKIN et al 433
Urbaitis BK (abst) 841
Uribarri JV (abst) 895
Urizar RE (abst) 782
USBERTI M, FEDERICO S, CIANCIARUSO B, COSTANZO R, RUSSO D, ANDREUCCI VE: Relationship between serum albumin concentration and tubular reabsorption of glucose in renal disease 546
Uvib Th (abst) 241

Vaamonde CA (abst) 778
Vacca C (abst) 853
Vacha G (abst) 223
Valdes AJ (abst) 782
Valentini R (abst) 653
Valette JP (abst) 241
Valtin H (abst) 784, 814
VAN ACKER KJ, SCHARPE SL, DEPRETTERE AJR, NEELS HM: Renin-angiotensin-aldosterone system in the healthy infant and child 196
Vanamee P (abst) 898
Van Berkestijn JWBM (abst) 532
Van Boven WPL (abst) 240
Van Breda Vriesman PJC (abst) 214
Van Damme B (abst) 659
Van Den Berg JV (abst) 781
Vanderbiesen V (abst) 532
Van der Hem GK (abst) 236, 240
Van der Woude FJ (abst) 214
Vandongen R (abst) 533
Vane JR (abst) 244
Van Elven EH (abst) 213
Van Eps LWS (abst) 904, 937
Van Es A (abst) 225
Van Es LA (abst) 215, 235
Vanherweghem JL (abst) 242
Vanholder R (abst) 533
Van Hooff-Eykenboom YEA (abst) 225
Van Leeuwen K (abst) 214
Van Liew JB: *see* GALASKE et al 394
Van Overbeek JJM (abst) 214
Van Rijswijk M (abst) 242
Van Rood JJ (abst) 225
Van Stelle J (abst) 790
Van Stone JC (abst) 790
Van Strien S (abst) 898
Van Wyk H (abst) 86
VAN YPERSELE DE STRIHOU C: Acute oliguric interstitial nephritis 751
Van Ypersele de Strihou C (abst) 98, 233
Van Zyl Smit R (abst) 91
Varenterghem Y (abst) 659
Vari R (abst) 842
Varney D (abst) 818
Vaughan ED Jr (abst) 906, 945
Vaz JR (abst) 875
Vaziri ND (abst) 893
Vázquez JM (abst) 861
Vecchierini-Blineau MF (abst) 659
Vehaskari VM (abst) 939
Velis O (abst) 651
Velosa JA (abst) 781, 788, 858, 938
Venkatachalam KK (abst) 782 (2), 790
Venkatachalam M (abst) 778
Venkatachalam MA: *see* SCHWARTZ et al 577
Venkatachalam MA (abst) 787, 857
Venuto R (abst) 921
Verani M (abst) 881
Verberckmoes R (abst) 533
Vercellone A (abst) 219, 650, 652
Verde de Martínez C (abst) 828
Vereerstraeten P (abst) 94
Verger C (abst) 97
Vergne PP (abst) 916
Vergne-Marini P (abst) 889
Veriava Y (abst) 91
Vernant JP (abst) 655
Vernier RL (abst) 810, 970
Verrier-Jones ER (abst) 92
Verrier-Jones K (abst) 92
VERROUST PJ, ADAM C, SMITH MD, RICHARD-LENOBLE D, KOURILSKY O, MOREL-MAROGER LJ: Circulating immune complexes and C3d in human parasitosis 9
Vertuno L (abst) 895
Verzetti G (abst) 654
Vestal RE: *see* ROWE et al 729
Vetter H (abst) 872
Vicenti F (abst) 942
Vilbar RM (abst) 889
Vinay P: *see* LEMIEUX et al 451
Vinay P (abst) 817
Vincenti F (abst) 242, 940, 948, 951
Virgi A (abst) 901
Vitale B (abst) 653
Vittinghus E: *see* MOGENSEN et al 385
Vizzo J (abst) 233
Vlasses PH (abst) 802
Vogel J (abst) 220, 923
Vogt A (abst) 217
Volanakis JE (abst) 935
Von Albertini B (abst) 222, 882, 883
Von Hartitzsch B (abst) 876, 888
Vonlanthen M (abst) 99
Vredevoe D (abst) 798
Vriesendorp HM (abst) 234

Wadhwa M (abst) 855
Waeber B (abst) 243
Wagoner RD (abst) 858
Wahren J (abst) 952
Walaszewski J (abst) 237
Waldherr R: *see* BOMMER et al 722
Walker BR (abst) 908
Walker RG (abst) 240
Walker WG (abst) 905, 907, 909 (2), 910 (2)
Wallace C (abst) 938
Walle AJ (abst) 242
Walling MW (abst) 826, 852, 856, 867
Walser M (abst) 865
Walsh PC (abst) 905
Wang KW (abst) 811
Wang LH (abst) 893
Wang M (abst) 865
Wang MS (abst) 824
Ward DM (abst) 801
Ward MK (abst) 230
Ward RA (abst) 955
Warnock DG (abst) 842 (2)
Warren E (abst) 886, 889 (2)
Warren SE (abst) 901, 909 (2), 924
Wasnick RJ (abst) 949
Wass VJ (abst) 93
Waterhouse RK (abst) 949
Waterloos MA (abst) 532
Wathen RL: *see* NAGAR and WATHEN 519
Wathen RL (abst) 955
Watkins JB (abst) 834
Wauters JP (abst) 243
Wayne DB: *see* KREISBERG et al 290
Weber DV (abst) 889
Weber PC (abst) 835
Wedeen RP (abst) 918
Wedgwood R (abst) 938
Weening JJ (abst) 213, 534
Weerts C (abst) 886
Weinberg JM (abst) 778, 860
Weinberger MH (abst) 795
Weiner B: *see* LAU et al 736
Weiner M (abst) 897
Weiner MW (abst) 771, 842, 879
Weinman EJ: *see* KNIGHT et al 572
Weinman EJ (abst) 824, 837, 843
Weinrauch LA (abst) 886, 949
Weinshilboum RM (abst) 954
Weinstein AM (abst) 836
Weinstein S (abst) 831
Weiss JH (abst) 879
Weiss MA: *see* OOI et al 681
Weiss MA (abst) 878, 931
Weizman A (abst) 888
Welbourne TC (abst) 810
Weller JM (abst) 949
Welling DJ (abst) 843 (2)
Welling LW (abst) 843 (2)
Wells G (abst) 892
Wells SA (abst) 952
Weseley S (abst) 923
West CD: *see* WYATT et al 505
Westbroek DL (abst) 234
Westenfelder C (abst) 774, 843, 844 (2)
Westervelt FB (abst) 864 (2)
Weston MJ (abst) 243, 244
Whalen JE (abst) 866
Whelton A (abst) 778
Whelton PK (abst) 905, 907, 909 (2), 910 (2)
Whitaker JM (abst) 817
White MG (abst) 889
White RI (abst) 905
Whitehouse R (abst) 818
Whiteley S (abst) 216
Whiteside G (abst) 240
Whiting PH (abst) 235
Whitley LA (abst) 875
Whittembury G (abst) 828
Widerøe TE (abst) 225
Wiesmann WP (abst) 844
Wijdeveld PGAB: *see* TIGGELER et al 312
Wilcox CS (abst) 809
Wilczewski T (abst) 860
Wilkes B (abst) 778
Wilkes JC (abst) 914
Wilkinson R (abst) 661
Will EJ (abst) 243
Williams A (abst) 869
Williams DG (abst) 660
Williams GM (abst) 905
Williams GW (abst) 949
Williams LA (abst) 92
Williams RH (abst) 879
Willis LR (abst) 786, 825
Wilson A (abst) 938
Wilson CB: *see* GOLBUS and WILSON 148
Wilson CB (abst) 783, 797, 799, 801, 848
Wilson D (abst) 837
Wilson DM: *see* JOHNSON et al 624
Wilson DM (abst) 812, 929
Wilson DR (abst) 838, 861
Wilson JA (abst) 243
Wilson PD (abst) 810, 844
Wilson T (abst) 873
Wilus PJ (abst) 906, 934
Winaver J (abst) 832, 834
Winchester JF (abst) 883 (2), 933, 950
Windhager EE (abst) 814, 826
Winer RW (abst) 884
Wing AJ (abst) 228, 232
Wing EJ (abst) 927
Wish JB (abst) 875
Witte JM (abst) 955
Wochos DN (abst) 822
Wolf A (abst) 224
Wolf C: *see* LAU et al 736
Wolf CJ (abst) 839
Wolf J (abst) 947
Wolfson M (abst) 955
Wong NLM (abst) 832, 845 (2)
Wong SF (abst) 661
Woodard T (abst) 889
Woods HF (abst) 243, 244
Worthen HG (abst) 914
Wright FS (abst) 815
Wright L (abst) 845

Wrona RM (abst) 901
Wu MJ (abst) 914
WYATT RJ, MCADAMS AJ, FORRISTAL J, SNYDER J, WEST CD: Glomerular deposition of complement-control proteins in acute and chronic glomerulonephritis 505
Wyndham R (abst) 907, 909, 910 (2)

Yahya TM (abst) 243
Yamada Y (abst) 235
Yamamura HI (abst) 914
Yamauchi J (abst) 235
Yanagawa N (abst) 787 (2)
Yarbrough SG (abst) 951
Yap P (abst) 891
Yarger WE (abst) 855
Yee VJ (abst) 842 (2)
Yevick J (abst) 892
Yoshiyama N (abst) 230
Young DB (abst) 845
Young J (abst) 924
Yuan L (abst) 850
Yudis M (abst) 901, 939
Yunis EJ (abst) 911

Zabel M (abst) 227
Zabetakis PM (abst) 891, 910
Zager RA (abst) 939
Zarco R (abst) 890
Zartnack F (abst) 217
Zawada ET (abst) 901, 910
Zazgornik J (abst) 227 (3), 238
Zech P (abst) 99
Zellerman G (abst) 234
ZENSER TV, MATTAMMAL MB, BROWN WW, DAVIS BB: Cooxygenation by prostaglandin cyclooxygenase from rabbit inner medulla 688
Zerefos N (abst) 902
Zevin D (abst) 888
Zick R (abst) 238
Ziegler R (abst) 218
Ziegler TW (abst) 846
Zimmerman D (abst) 823
Zimmerman MB (abst) 802
Zimmerman SW (abst) 790, 926
Zingraff J (abst) 221, 244
Zmuda MJ (abst) 902
Zollinger HU (abst) 651
Zucchelli P (abst) 653
Zuin R (abst) 651

Subject Index for Volume 16

Acetate-free HCO_3 buffered dialysate (abst) 223
Acid-base equilibrium
  normal plasma bicarbonate concentration as redefinition of normal 612
  systemic, stironolactone effect (abst) 821
Acid-base homeostasis
  hemofiltration (abst) 882
Acid excretion
  induction by parental feeding (abst) 813
Acidosis
  ammoniagenic plasma factor in acute (abst) . . . 846
  intracellular potential and K^+ activity in metabolic and respiratory (abst) 809
  renal ammonium production and amino acid uptake in acute metabolic (abst) 651
Adenylate cyclase
  -AMP systems (abst) 841
Adenylate cyclase kinetics
  altered (abst) 852
ADH-stimulated water permeability
  inhibition of (abst) 872
Alanine metabolism effect
  in isolated dog kidney tubule (abst) 654
Albumin
  renal handling of 366
Albumin excretion
  abnormal 385
Aldosterone
  in conscious Brattleboro strain rats (abst) 873
  metabolic effects of (abst) 842
Alkaline phosphatase activity
  along nephron of genetic hypophosphatemic mice (abst) 849
Alkalosis
  formula induced (abst) 921
Allograft rejection
  MHC antigens and (abst) 862
Allograft survival rates
  blood transfusion effect on (abst) 864
Allograft transplantation
  cimetidine and (abst) 863
Alloimmune memory cells
  mitogenic oxidizing agent detection of (abst) . . 949
Amberlite XE-336 resin
  uremic dog blood perfusion of (abst) 897
Amino acid uptake
  insulin-mediated (abst) 865
Amino acids
  as dextrose replacement (abst) 780
Aminoglycoside nephrotoxicity
  urinary markers of (abst) 241
Ammoniagenesis
  acute acidosis stimulation of (abst) 840
Anemia
  in hemodialyzed patients (abst) 659
Anephric diabetes
  hyperglycemia in (abst) 886
Anephric patients
  plasma 25-OH and (abst) 649
Anesthetics
  glomerular filtration rate and (abst) 814
Angiotensin
  vascular hyporesponsiveness to (abst) 790
Angiotensin blockade
  renal and single nephron absorptive function during (abst) 831
Angiostensin II
  contributions to glomerulotubular balance of (abst) 821
  dietary sodium depletion effect on (abst) 794
  hypotensive and natriuretic action of captopril due to inhibition of (abst) 794
  low sodium diet and propranolol effect on (abst) 873
  reversal of renal cortical action of 137
Angiotensin II and III
  cardiovascular responses to (abst) 803
Antacids
  phosphate-binding properties of 950
Antiglomerular basement membrane disease
  circulating immune complexes in (abst) 661
Anti-HLA immunization
  in hemodialyzed patients (abst) 222
Antitubular basement membrane antibodies
  radioimmunoassay detection of (abst) 95
Arginine vasopressin
  low sodium diet and propranolol effect on (abst) 873
Arteriovenous fistulae
  blood flow in chronic hemodialyzed patients (abst) 220
  doppler ultrasound determination of effect of (abst) 884
  hemodynamic dangers of (abst) 218
  localized infections of (abst) 948
  using anastomotic flange (abst) 916
  xeroradiographic studies of (abst) 916
ATP
  ouabain effect on ischemia-induced changes of (abst) 841
Avascular necrosis
  detection of early (abst) 220

Bacteriuria
  bacteriologic follow-up of untreated (abst) . . . 92
Baroreflex dysfunction
  in adult onset diabetics (abst) 922
Baroreflex sensitivity
  prazosin and (abst) 907
Bartter's syndrome
  absence of juxtaglomerular apparatus hyperplasia and (abst) 925
  indomethacin treatment of (abst) 86
  naproxen treatment of (abst) 933
  physiologic and pharmacologic studies of (abst) . 929
  and pseudo-Bartter's syndrome, plasma and urinary prostaglandin measurement in (abst) . . . 657

Bence Jones protein
acute nephrotoxicity of (abst) 879
nephrotoxicity of (abst) 920
in rat, nephrotoxicity of 345
Berger's disease
polymeric IgA levels in (abst) 228
Beta$_2$ microglobulin
loading effect on renal extraction of low molecular weight proteins (abst) 853
Bicarbonate permeability
in superficial and deep proximal convoluted tubules (abst) 820
Bicarbonate reabsorption
limitations on (abst) 811
Blood pressure
urea and angiotensin II effect on (abst) 792
Blood pressure protection
during ultrafiltration (abst) 889
Blood pressure recording
new method of (abst) 905
Blood pressure regulation
parathormone vasodepressive effect on post-transplant (abst) 231
Blood pressure variance
renin substrate and potassium contributions to (abst) 909
Blood volume expansion
natriuresis and filtration fraction effect on (abst) 90
Bone
1,25(OH)$_2$D$_3$ and 24,25(OH)$_2$D$_3$ action on (abst) 828
Bone disease
in children (abst) 218
dyhydrotachysterol in (abst) 891
oxalosis-induced (abst) 885
softened or deionized water (abst.) 87
vit. D and (abst) 219, 953
Bumetanide transport
by rabbit renal cortex slices (abst) 816

Calcium
as cause of defective blood clearance and deposition of soluble aggregates of IgG (abst) 798
loading effect on plasma and urinary acid-base equilibrium (abst) 821
Calcium, cytosolic
quinidine effect on transport role of (abst) 803
Calcium nephrolithiasis
calcitonin in (abst) 919
Calcium release
cAMP dependent protein kinase effect on (abst) . 844
Calcium transfer
during hemodialysis and hemofiltration (abst) . . 883
Calcium transport
heterogeneity in thick ascending limb of Henle (abst) 840
inhibitor effect on renal hemodynamics and electrolyte excretion (abst) 857
mechanism, bidirectional active (abst) 856
by proximal tubule (abst) 815
PTH-induced (abst) 837
Captopril
responsiveness to exogenous angiotensin I and II and bradykinin after (abst) 904
Cardiac tamponade
body fluids and chronic (abst) 856
Cardiomegaly
chronic haemodialysis patients with (abst) . . . 221
Cardiothoracic ratio
as index of body fluid balance (abst) 236
Cellular metabolism rate
regulation by changing H^+ of turtle bladder by changing free energy of ATP hydrolysis (abst) 811
Charcoal, oral
serum lipids and lipoproteins patterns (abst) . . . 867
CHF
dose-response curve in (abst) 919
Chloride
conductive entry into brush border vesicles of (abst) 842
Chloride permeability
in superficial and deep convoluted tubules (abst) 820
Chloride transport
in isolated rabbit cortical collecting tubule (abst) 821
Cimetidine effect
on water and sodium transport (abst) 819
Cirrhosis
impaired water excretion in (abst) 873
renal prostaglandin E augmentation in (abst) . . 920
Cis-diamminedichloroplatinum
pathologic effects of (abst) 772
renal handling of (abst) 879
Citrate synthase activity
mineralocorticoid target sites and (abst) 828
Citrate transport
by luminal and contraluminal membrane vesicle (abst) 829
Classical complement pathway
characteristics of nephritic factor of (abst) . . . 657
Cold diuresis
mechanism of (abst) 868
Collecting duct
bicarbonate transport (abst) 827
NH_3 added to rat (abst) 837
Collecting duct hydrogen ion secretion
acute furosemide administration on (abst) 815
extracellular fluid volume effect on (abst) 860
Collecting duct luminal membrane
urine concentration and (abst) 871
Collecting duct segment
chloride reabsorption (abst) 824
Cortical collecting tubules
absence of effect of PGE_2 on transepithelial potential difference in (abst) 813
acidification of luminal fluid by (abst) 824
chloride transport stimulation by isoproterenol in (abst) 821
contrasting shape and basal infolding in light and dark cells of (abst) 843
hydro-osmotic response (abst) 874
potassium and magnesium secretion in (abst) . . 825
prostacyclin influence on transepithelial potential difference in (abst) 822
Creatinine phosphokinase
uremic myopathy and (abst) 923
Cyclic AMP production
ouabain effect on basal and PTH stimulated (abst) 844

Cyclic AMP stimulation
of sodium transport and urea permeability (abst) 822
Cytotoxic antibody
removal (abst) 950
Cytotoxic T cell abrogation
mitogenic oxidizing agent and (abst) 864
Cytotoxicity
donor-specific antibody evaluation of (abst) . . . 864

Delayed cutaneous hypersensitivity
antigens (abst) 943
Diabetes
glomerular function and insulin effect in alloxan (abst) 786
hyperchloremic acidosis during (abst) 921
insulin and glucagon effect on glomerular RNA in (abst) 790
uremic long-term (abst) 224
urinary kallikrein excretion in alloxan induced (abst) 783
Dialysis
acetete versus bicarbonate (abst) 233, 881
aluminum, EEG and intellectual function in (abst) 223
chronic
atherosclerotic risk factors in (abst) 888
hyperprolactinemia and impotence in (abst) . 888
malignancy incidence and (abst) 892
self-dialysis use in (abst) 890
volume and solute excretion of saliva in (abst) 915
contaminated dialysate (abst) 896
glycosylated hemoglobin measurements in diabetic and non-diabetic (abst) 901
H^+ balance measurement during acetate and bicarbonate (abst) 887
home
hemodialysis versus CAPD in (abst) 892
spouse relief for (abst) 899
tuberculosis peritonitis in (abst) 900
hyperosmotic
peritoneal clearance increase and (abst) 892
nutritional therapy and reduced frequency (abst) 894
parietal peritoneum participation in (abst) 227
peritoneal
chronic ambulatory (abst) 240
clearances in patients undergoing continuous ambulatory 619
continuous ambulatory (abst) 234, 893
gastrointestinal hormone effect on 130
glucose absorption during (abst) 888
hemodynamics in (abst) 238
high risk ESRD patient continuous ambulatory (abst) 895
hyperglycemia control in automated (abst) . . 915
in ketosis-susceptible diabetes mellitus (abst) . 226
lipoprotein metabolism and (abst) 954
metabolic balance and (abst) 882
metabolic effect of continuous ambulatory (abst) 892
new set of (abst) 894
nitrogen and urea metabolism during (abst) . . 882
peritoneal fluid and (abst) 228
after peritonitis (abst) 897
renal transplantation in (abst) 896
stagnant fluid films effect on (abst) 780
tobramycin pharmacokinetics in (abst) 896
in treatment of end-stage renal failure (abst) . 94
unsafe automatic (abst) 86
prolactin, zinc and sexual activity in (abst) . . . 219
raised calcitonin and (abst) 88
Dialysis cardiomyopathy
factors responsible for (abst) 89
Dialysis dementia
new approach to early detection of (abst) 216
transplantation effect on (abst) 220
Dialysis encephalopathy
aluminum concentration and (abst) 90
Dialysis initiation
cardiac abnormalities in uremia prior to (abst) . . 881
Dialysis-respiratory distress syndrome (abst) . . . 899
Disequilibrium pH
reevaluation by direct in vivo determination (abst) 811
Distal tubular fluid
composition and tubuloglomerular feedback responses of (abst) 806
DNA/anti-DNA complexes
in systemic lupus erythematosus and idiopathic nephritis (abst) 660
Dopamine
as natriuretic factor in rats (abst) 804
Drug metabolizing enzymes
plasticiser influence on (abst) 241
Ductal obstruction
in diphenylthiazole-induced renal cystic disease (abst) 902

Emetic reflex influence
on vasopressin-release in man 719
Enantiomers of MK-196
natriuretic activity of (abst) 802
Endogenous prostaglandins
renal vascular tachyphylaxis and (abst) 857
Endothelial antibodies
in alloimmune sera (abst) 864
Endoxin
detection of endogenous digoxin-like substance in plasma of dog, sheep and man (abst) 817
Enzymatic digestion
removal of glycosaminoglycans by (abst) 823
Epithelial sodium transport
blockade by tyrosine-specific reagents of (abst) . 831
large anions as potential endogenous regulators of (abst) 846
Epithelium
aminonucleoside effect on (abst) 848
sucrose, inulin and dextran and leaky (abst) . . . 828
Erythrocyte membrane ATPase activity
chronic peritoneal dialysis and (abst) 885
Erythrocyte organic phosphates
hemofiltration and hemodialysis effect on (abst) . 232
Erythropoietin
effect on erythron of anephric rat of (abst) 790
Extracellular fluid volume measurement
plasma volume and 850

Extrarenal acid buffering
PTH action and (abst) 846

Fabry's disease
fetal liver transplant in (abst) 229
Fluoride
inhibition of renal Na-K-ATPase by (abst) . . . 843
Focal glomerular sclerosis
in aging Sprague-Dawley rats (abst) 848
minimal lesions and (abst) 214
Furosemide
effect of glomerular filtration 672
effect on low Cl, low Na diet (abst) 829
and indomethacin in volume expanded and non-volume expanded dogs, renal effects of (abst) . 792
Furosemide-probenecid interaction
pharmacodynamics of 187

Gamma$_{2U}$-globulin, dietary control of renal reabsorption and excretion of 409
Gentamicin
induced β_2 microglobulinuria (abst) 923
pinocytosis role in toxicity of (abst) 855
renal handling of (abst) 837
renal tubular transport of 440
tobramycin clinical nephrotoxicity compared to (abst) 878
Gentamicin interaction
with luminal and antiluminal nephron surfaces (abst) 859
Glomerular albumin filtration
in rat kidney 377
Glomerular barrier function
proteinuria selectivity index in (abst) 928
Glomerular basement membrane
in glomerular selective protein filtration (abst) . 99
Glomerular basement membrane antigens
human antibody reaction with collagenase solubilized human (abst) 797
in urine, physicochemical characteristics of . . . 322
Glomerular bound immune complexes
cell mediated reaction against (abst) 796
Glomerular capillaries
macromolecule transport across 353
Glomerular cells
complement or IgG-Fe receptors and glomerular antigens in (abst) 95
complement receptors in E. coli-injected rats (abst) 97
synthesis of PGE by (abst) 826
Glomerular dynamic studies
errors inherent to (abst) 829
Glomerular epithelial cells
phagocytosis inhibition by cytochalasin (abst) . 836
prostaglandin and thromboxane synthesis by (abst) 858
Glomerular fibrinolytic activity
circulating inhibitor of (abst) 926
Glomerular filtration
aspirin effect on (abst) 917
changes during ureteral obstruction (abst) 853
during furosemide diuresis 665
inulin versus creatinine as measure of (abst) . . . 853
uremic hyperprolactinemia (abst) 866
Glomerular function
tobramycin versus gentamicin effect on (abst) . . 776
Glomerular human collagen antigens (abst) 811
Glomerular immune injury
antiglomerular basement membrane antibody induced 848
gentamicin induced salt susceptible hypertension following (abst) 786
reticuloendothelial stimulation protective role in (abst) 800
Glomerular lesions
in spontaneous hypertensive rat (abst) 793
Glomerular mesangium
cell contraction (abst) 804
IgA aggregates in (abst) 801
pancreatic islet transplantation effect on (abst) . 786
Glomerular nephropathies
C3d measurements in chronic primary (abst) . . 657
chemically induced (abst) 926
Glomerular permeability coefficient
euvolemic expansion of (abst) 841
Glomerular preselectivity
in chronically diabetic rats (abst) 787
Glomerular wall
altered change and size selective properties of (abst) 857
Glomerulonephritis
actuarial survival in adult primitive (abst) 653
acute poststreptococcal (abst) 933
chemical structure of glomerular basement membrane in experimental (abst) 785
circulating immune complexes in pathogenesis of primary (abst) 654
complement breakdown products and immune complexes in plasma patients with (abst) . . . 650
of congenital syphilis (abst) 652
crescentic
in children (abst) 937
immune versus non-immune pathogenesis of (abst) 911
treatment and outcome in (abst) 924
epimembranous
immune complexes in (abst) 913
essential mixed cryoglobulinemia (abst) 651
experimental immune complex
macrophage/monocyte participation in (abst) . 783
in familial cryoglobulinemia (abst) 934
filtration in isolated glomeruli and (abst) 788
glomerular deposition of complement-control proteins in 505
HLA Bw35 antigen and mesangial IgA (abst) . . 217
idiopathic
circulating immune complexes in (abst) 911
induced by immune complex formation in glomerular capillary wall 148
lupus
polynucleotide complexes in (abst) 800
lymphocyte markers and circulating immuno complexes in primary (abst) 232
malarial (abst) 789
membranoproliferative C3 activating factor in (abst) 913
mesangiocapillary (abst) 93, 928

models for (abst) 213
passive immune complex (abst) 782
plasmapheresis treatment of (abst) 927
primary chronic (abst) 650
proliferative (noncrescentic) (abst) 656
recurrent rapid progressive (abst) 924
rheumatoid arthritis and (abst) 89, 936
serum sickness (abst) 213
suppressor cell function in immune complex (abst) 914
thyroglobulin antigen-antibody complex and immune complex (abst) 912
Glomerulopathies
composition of cryoprecipitable immune complexes in (abst) 810
glomerular immune complex aggregates in passive serum sickness 531
mercury-induced, nuclear antigen in (abst) . . . 534
schistosomal 23
transplant ultrastructure of (abst) 951
Glomerulosclerosis
experimental focal effects of hyperlipidemia and halofenate (abst) 799
indomethacin treatment influence on spontaneous (abst) 659
Glomerulotubular balance
contributions of angiotensin and prostaglandin to (abst) 831
in experimental glomerulonephritis (abst) 864
Glucocorticoids
in renal patients (abst) 952
calcium excretion and (abst) 844
magnesium and (abst) 844
in renal lymph (abst) 820
Glucose absorption
in proximal convoluted tubule (abst) 834
Glucose tolerance
in patients on hemodialysis and (abst) 222
Glutaminases (abst) 810
Glutamin metabolism
lactate and 451
Glycosaminoglycan synthesis
by glomeruli (abst) 818
Goodpasture antigen
localization (abst) 930
Goodpasture's syndrome
circulating anti-GBM antibody and (abst) 93
Guanabenz
racial differences in response to hydrochlorothiazide and (abst) 919
Guanine nucleotide effect
on vasopressin-induced increment of osmotic water flow and adenylate cyclase activity (abst) 838

Heart failure, congestive
plasma arginine vasopressin levels by radioimmunoassay in (abst) 967
Hemochromatosis
hemodialysis-associated (abst) 893
Hemodialysis
abnormal platelet deposition and (abst) 925
acute internal hemorrhage and (abst) 97
amino acid infusion during (abst) 965
catecholamine levels and hypotension with abst . 654
cellular respiration and (abst) 97
in children (abst) 656
chronic
acquired kidney cystic disease and (abst) . . . 903
fluoxymesterone metabolic effect in (abst) . . 896
hyporeninemia and hypoaldosteronemia in (abst) 901
iron-induced hemochromatosis in (abst) . . . 893
RBC 2-3 DPG, O_2 tension and hematocrit in (abst) 929
vancomycin therapy and (abst) 891
erythropoietin levels and (abst) 242
exercise induced reduction in blood pressure in (abst) 920
femoral vein single-needle (abst) 897
gross hematuria in (abst) 911
high and low sodium (abst) 905
hydrostatic ultrafiltration during (abst) 895
hypoventilation and hypoxemia during (abst) . . 905
impaired gastric emptying and (abst) 962
intracellular free amino acids and 216
iron overload and (abst) 890
leukopenia, hypoxia and complement function in (abst) 900
maintenance
calcitonin and parathyroid hormone secretion during (abst) 902
hypertensive risk normalization in (abst) . . . 897
propranolol metabolite retention in (abst) . . . 910
serum ferritin and (abst) 900
mitogen-induced lymphocyte transformation during (abst) 229
nerve entrapment syndromes and (abst) 886
non A, non B hepatitis and (abst) 217
pediatric, sodium dialysate use in (abst) 897
prothrombotic state induced by (abst) 243
repeated acute, indwelling intravascular introducer sheath for (abst) 898
in schizophrenia (abst) 240, 242, 914
serum calcium component changes after (abst) . 879
solute kinetics as assessment of nutritional status in (abst) 898
sympathetic activity and hemodynamics in (abst) 891
thermography for vascular access survey in (abst) 230
thyroid function tests and (abst) 87
vascular access survey in (abst) 657
vasopressin response and (abst) 234
volume depletion and (abst) 224
water treatment for (abst) 94
Hemodialysis centers
hepatitis B in (abst) 894
Hemodialysis encephalopathy, osteomalacic
osteopathy and electroencephalographic changes as premonitory signs of (abst) 659
Hemodialysis membranes
cellulose, solute permeability and rejection characteristics of (abst) 226
Hemodialysis unit
computer graphics in (abst) 223

Hemofiltrate
intestinal recycling and substitution of (abst) . . 228
Hemofiltration
altered lipid and insulin response in hemodialysis after (abst) 898
evaluation of benefits of (abst) 238
high flux, vascular resistance and stability during (abst) 899
hypertension and/or acute pulmonary edema (abst) 898
sympathetic activity and hemodynamics in (abst) 891
uremic toxin removal by (abst) 225
vascular stability during (abst) 239
Hemofiltration-hemodialysis
kinetics of gentamicin and tobramycin during sequential (abst) 902
Hemofiltration membranes
evaluation of (abst) 779
Hemolytic uremic syndrome (abst) 922
Hemoperfusion effect
in lean versus fat intoxicated dogs (abst) 902
Henle's loops
specialization in thin limbs of 577
Heparin
gabexate mesilate and (abst) 230
Hepatitis B core antigen in hemodialysis patients
point prevalence of antibody to (abst) 780
Hepatitis B incidence
multiple usage of dialyzers and (abst) 887
Hepatitis Be antigen
and its antibody in urine of hemodialysis and transplant patients (abst) 779
Hepatitis profile
in "hepatitis free" unit (abst) 884
Hepato-renal syndrome
acute portal hypertension and (abst) 649
Hepato-splenomegaly
with ascites and foam cells (abst) 894
Histamine effect
on water and sodium transport (abst) 819
Hyalinized glomeruli
molecular pathobiology of (abst) 862
Hydrochlorothiazide
guanabenz and (abst) 924
Hydrogen ion secretion
cyclic AMP effect on 103
distal nephron and (abst) 817
in turtle bladder (abst) 836
Hypercalcemia
chlorthalidone induced (abst) 921
Hypercalciuria
acid versus neutral phosphate therapy of 726
diagnostic approach to 637
in recurrent stone-formers, thiazide use in prevention of (abst) 649
renal mechanism in spontaneous (abst) 861
thiadize diuretics in (abst) 216
urinary magnesium excretion in (abst) 232
Hyperchloremic metabolic acidosis
renal transplant chronic rejection and (abst) . . . 940
Hypercoagulability
heparin induced (abst) 896
Hyperlipidemia
of children with kidney transplants (abst) 945
post-transplant (abst) 233
Hypernatremia
GFR suppression during acute (abst) 808
hypercalcemia and (abst) 88
post-transplant
ionized calcium and (abst) 231
parathyroid hormone secretion in (abst) . . . 946
PTH response to EDTA infusion and (abst) . . 946
Hyperphosphatemia role in vitamin D
metabolite effect on osteitis fibrosa in patients on chronic hemodialysis (abst) 656
Hyperplasia, epithelial
as cause of ductal obstruction in adult polycystic disease 743
Hypertension
in adult onset diabetics (abst) 907
arginine vasopressin in essential (abst) 904
arterial, in newborn period (abst) 936
captopril and salt subtraction treatment of (abst) 243
captopril treatment of (abst) 236
corticotrophin-induced (abst) 904
dialysis-resistant, renin-angiotension system and blood volume in 532
diazoxide infusion in treatment of severe (abst) . 905
diuretic effect on renin in treatment of essential (abst) 907
double blind placebo controlled protocol of captopril in (abst) 908
due to renin-secreting renal tumor (abst) 658
effects of 1-Sar, 1-Ile-angiotension II in malignant human (abst) 654
in end-stage renal disease, captopril therapy of (abst) 906
following unilateral posttraumatic renal polar atrophy, delayed (abst) 659
hemofiltration control of (abst) 779
initial diuretic therapy in (abst) 910
lofexidine in treatment of (abst) 905
low plasma renin activity in essential (abst) . . . 910
minoxidil treatment of (abst) 214, 903
Na and K in erythrocytes and (abst) 95
NaCl, circulating humoral pressor agent in Dahl S rats with (abst) 796
natriuresis of (abst) 220
neonatally induced coarctation
acute converting-enzyme inhibitor effect on proximal pressure and plasma renin activity in (abst) 791
renin reactivity (RR), renin substrate (RS), and plasma renin concentration (PRC) in serially studied inbred dogs with (abst) 792
in parenchymatous renal disease (abst) 661
prazosin and methyldopa in (abst) 909
primary kidney abnormality as cause of essential (abst) 651
reduction in net sodium efflux in erythrocytes of rats (abst) 656
renal, intracerebroventricular saralasin in acute and chronic phases of (abst) 793
renin-sodium profile based therapeutic approach in (abst) 907

renovascular
computerized tomography in (abst) 906
medical and surgical therapy follow-up of (abst) 905
saralasin infusion in (abst) 908
in South African black population (abst) 91
urinary kallikrein and (abst) 903
wytensin and placebo compared with wytensin and hydrochlorothiazide in (abst) 908
Hyperuricemia
as index of renal involvement in essential hypertension (abst) 906
Hypochloremia effect
during volume expansion (abst) 852
Hypocomplementic vasculitis-urticaria syndrome
renal involvement in (abst) 935
Hypoglycemia
malignant hypertension associated with propranolol induced (abst) 906
Hypokalemia
renal chloride reabsorption in diagnosis of (abst) 929
vasopressin-dependent cyclic AMP suppression as cause of polyuria of (abst) 853
Hyponatremia
protracted (abst) 955
Hypophosphatemia
kidney graft and (abst) 229
Hypophosphatemic rickets (abst) 928
Hypotension
oral parenteral phenylephrine for (abst) 901
Hypothermic preservation
canine kidney function and ultrastructure change during isolated (abst) 948

IA antigens
expression of (abst) 863
Idiopathic edema
in popliteal fossa (abst) 95
Idiopathic hematuric syndromes
primary basement membrane attenuation in (abst) 927
Idiopathic membranous glomerulonephropathy
pathogenesis of immune defect in (abst) 912
Idiopathic urolithiasis
parathyroid function in (abst) 932
IgG
heat-aggregated and monomer (abst) 859
Immune complex assays
in serum (abst) 650
systemic lupus erythematosus management and (abst) 660
Immune complex disease
plasma exchange in (abst) 225
Immune-complex load
complement function and (abst) 92
Immune complexes
in choroid plexus, binding sites for (abst) 912
in epimembranous glomerulonephritis (abst) . . 913
mononuclear phagocyte elimination of (abst) . . 215
renal vein constriction effect on 681
Immunoglobulin synthesis
unbalanced (abst) 929
Immunoreactive rat growth hormone
renal handling of (abst) 816
Inner medullary collecting duct
effect of volume expansion on sodium and chloride transport along rat (abst) 806
Insulin
peritubular metabolism of (abst) 833
renal excretory responses to (abst) 834
Intestinal electrolyte transport
acute metabolic alkalosis and acidosis effect on in vivo (abst) 813
Intracellular electrolyte
flush kidney preservation (abst) 939
Intravenous pyelogram
basophil degranulation test and (abst) 650
Inulin
as marker of glomerular filtration rate 179
Ischemic colitis
and hemolytic uremic syndrome (abst) 888
Ischemic heart disease
in patients with uremia undergoing maintenance hemodialysis 600
Isoproterenol
stimulation of chloride transport in isolated rabbit cortical collecting tubule by (abst) 821

Juxtamedullary nephron
response to volume expansion and furosemide (abst) 857

K, *see also* Potassium
K depletion
effect on renal Cl-conservation (abst) 854
renal and systemic acid-base response to dietary (abst) 854
thromboxane (TXA_2) and prostaglandin E (PGE) in (abst) 848
K excretion
ammonia production and (abst) 835
renal components of feed-dependent (abst) . . . 833
K transport
acute acidemia and alkalemia effect on distal convoluted tubule (DCT) (abst) 839

Lanthanum effect
on water and sodium permeability (abst) 819
Lipoprotein
triglyceride transport (abst) 868
Lithiasis
phosphatic and oxalic (abst) 659
Lithium
urinary elimination of (abst) 96
Lithium toxicity
associated with peripheral edema (abst) 937
Liver cirrhosis
portal-systemic shunt and (abst) 651
Liver growth factors (abst) 805
Living related donor renal recipients
pretransplant evaluation of (abst) 862
Luminal membranes
vasopressin induced aqueous channels in (abst) . 872

Lupus disease
immune complexes in (abst) . . . 658
Lupus erythematosus, systemic
in childhood (abst) . . . 938
methylprednisolone "pulse" therapy in children with (abst) . . . 937
suppressor cell function and (abst) . . . 89
syndrome, T-B cell (abst) . . . 213
Lupus nephritis
circulating anticoagulants with anti-prothrombinase activity in (abst) . . . 657
coagulation role in (abst) . . . 931
immunofluorescent studies of skin (abst) . . . 936
predialysis experience in (abst) . . . 926
Lymph
formation rate (abst) . . . 830
Lymphocyte culture suppressor cells
in vitro generation of (abst) . . . 863
Lymphocyte subpopulations
in minimal change nephropathy (abst) . . . 653
Lymphocytes
oral isoniazid effect on (abst) . . . 90
Lysosomal enzymes
in glomeruli of normal and nephrotic rat kidney (abst) . . . 858

Macromolecular localization
charge effect on kidney (abst) . . . 810
Magnesium
calcitonin effect on reabsorption of (abst) . . . 832
tubular maximum reabsorptive capacity for (abst) . . . 845
Magnesium deficiency
negative potassium balance in (abst) . . . 852
Magnesium depletion
skeletal muscle injury after (abst) . . . 865
tubular PO_4 transport in (abst) . . . 851
Magnesium metabolism
1,25$(OH)_2$-vitamin D effect on (abst) . . . 867
Magnesium transport
in cortical thick ascending limb of Henle (abst) . 837
Maleic acid
induced Fanconi's syndrome (abst) . . . 919
Malignant histiocytosis
revealed by nephrotic syndrome (abst) . . . 96
Malignant uroepithelial tumors
analgesic-associated nephropathy and (abst) . . 97
Mannitol diuresis
response of deep nephrons and collecting duct to (abst) . . . 832
Mannitol intoxication
severe (abst) . . . 882
Medullary collecting duct
electrical properties of rat (abst) . . . 819
urea reabsorption and secretion in (abst) . . . 838
Membranoproliferative glomerulonephritis
antigenic composition of glomerular capillary in (abst) . . . 851
complement pattern in (abst) . . . 649
Memory cells
detection of (abst) . . . 240
Memory response
second set rejection and (abst) . . . 863

Mercuric chloride effect
on ^{36}Cl fluxes . . . 860
Mesangial IgA nephropathy
HLA and (abst) . . . 911
Mesangial immune complex injury
impaired mesangial clearing of macromolecules in chronic (abst) . . . 784
Mesangial immune deposits
pathogenetic role of (abst) . . . 217
Metabolic acidosis
by chronic vit. D therapy (abst) . . . 854
intestinal absorption of calcium and phosphorus in (abst) . . . 852
Metabolism
Ac and HCO_3 infusion effect on (abst) . . . 955
Mineral-acid loading
role of anion-mediated extra-renal factors in body's response to chronic (abst) . . . 808
Mineral homeostasis
interaction between magnesium and vitamin D and (abst) . . . 826
Mononuclear phagocytic system
normal handling of macromolecular species by (abst) . . . 798

Na, *see also* Sodium
Na excretion
angiotensin II effect on (abst) . . . 921
in salt sensitive and resistant rats (abst) . . . 791
Na permeability
regulation by intracellular Na^+ and Ca^{++} (abst) . 809
Na transport
dose-response relationships of (6,7-dichloro-2-methyl-1-oxo-2-phenyl-5-indanyloxy) acetic acid (MK-196) and isomers of isolated frog skin on (abst) . . . 812
separate pathways for basal and hormone-stimulated (abst) . . . 814
sugar transport in cultured epithelial cell line (abst) . . . 833
Natriuretic agent
effect on nephrogenous cyclic AMP added to renal vein (abst) . . . 817
Natriuretic hormone
prostaglandin release and (abst) . . . 223
Natriuretic hormone production
by isolated rat kidneys, necessity of prostaglandin for (abst) . . . 655
Necrosis, acute tubular
phospholipid metabolism in (abst) . . . 777
Necrotizing cutaneous vasculitis
PVC plastic tubing as cause of (abst) . . . 218
Nephrectomy
immunoreactive glandular kallikrein in rat plasma after bilateral (abst) . . . 785
Nephritis
acute oliguric interstitial . . . 741
autologous immune complex suppression (abst) . 797
hereditary, HLA typing and hydroxylsine glycosides in pedigree analysis of (abst) . . . 911
Heymann
antibody mediated injury to proximal tubules in (abst) . . . 797

deposition of immune complexes and (abst) . . 216
eluted antibody reactivity in (abst) 799
in-situ immune complex formation in (abst) . . 798
immune complex charge role in experimental (abst) 796
interstitial
immunologic function and lymphocyte diversity in (abst) 799
lymphocyte-mediated fibrogenesis in (abst) . . 799
lupus, *see* Lupus nephritis
Masugi, excretion and synthesis of basement membrane disaccharide units in 329
nephrotoxic
in isolated perfused rat kidney (abst) 797
polyanion alteration of glomerular filtration barrier in complement independent (abst) . 784
relationship between proteinuria, foot process (fp) fusion and alterations in anionic sites in puromycin nephrosis and (abst) 788
nephrotoxic serum
parathyroidectomy effect on (abst) 789
rapid and focal loss of negative charge associated with mononuclear cell infiltration early in 290
plasmodium infection and 53
SLE, *see also* Lupus erythematosus, systemic
elective plasmapheresis in (abst) 928
nuclear antigen antibodies and (abst) 924
tubulointerstitial, urinary protein indices of (abst) 939
Nephrocarcinoma
elevated urinary kallikrein excretion as marker for (abst) 934
Nephrogenic diabetes insipidus
pathogenesis of (abst) 784
Nephrology
disease activity detection in (abst) 219
Nephron
potassium adaptation site in (abst) 811
Nephron function
diazoxide effects on 532
Nephron glomerular filtration
effects of early papillary necrosis on deep (abst) . 788
Nephron PO_4 transport
nephron heterogeneity in superficial and deep (abst) 816
Nephropathy
autoimmune glomerulotubular genetic influences in development of (abst) 781
autologous immune complex indomethacin-induced reversal of severe proteinuria with (abst) 785
Berger's, intra-renal vascular disease in (abst) . 929
diabetic
eye surgery and (abst) 914
platelet inhibitor treatment of (abst) 915
gout (abst) 918
hereditary, ultrastructural changes in (abst) . . . 925
IgA, in children (abst) 932
lupus, pregnancy and (abst) 931
membranous
prednisone alternate-day treatment of (abst) . 939
renal biopsy features of (abst) 931
progressive renopenic (abst) 790
vesicoureteral reflux (abst) 938
Nephrosis
aminonucleoside
alteration in charge and size selectivity barrier of glomerular filter in (abst) 787
glomerular cyclic AMP and cyclic GMP response to hormonal agents in (abst) 788
Nephrotic syndrome
in Africans and Indians of South Africa (abst) . . 90
age related histology in minimal change (abst) . . 861
in aged adults (abst) 99
associated with T-cell lymphoma (abst) 655
in black and white children (abst) 88
cardiovascular disease risk and (abst) 93
cyclophosphamide in childhood (abst) 930
glycosidase treated glomerular basement membrane in minimal change (abst) 927
immune complex induced Heymann nephritis similarity to (abst) 912
indomethacin effect on glomerular permeability in 312
lymphocyte subpopulations in minimal change (abst) 913
normal renal function and (abst) 920
plasma renin activity and substrate levels in patients with (abst) 531
platelet hypersensitivity in (abst) 236
pneumococcal vaccination in (abst) 914
recanalization of renal vein thrombosis and (abst) 932
relapsing
in children 75
renal glycosuria and (abst) 98
renal histamine abnormal dynamics in (abst) . . 781
renal salt retention mechanisms in experimental (abst) 783
renin-angiotensin-aldosterone system role in (abst) 660
sodium retention in 561
in South African children (abst) 86
water immersion induced diuresis in (abst) . . . 927
Nephrotoxicity
aminoglycoside, hyperalimentation effect on (abst) 778
asymptomatic arsine (abst) 88
cisplatin, chronic salt loading effect on rat (abst) 777
gentamicin-induced (abst) 235, 773, 775
mitomycin C treatment of (abst) 99
molecular basis of aminoglycoside and diethylaminoethyl dextran (abst) 778
volume depletion in furosemide enhanced aminoglycoside (abst) 771
Neuropathy
hemodialysis and transplantation effect on autonomic (abst) 243
short time hemodialysis and (abst) 224
Nicotinamide adenine dinucleotide
in isolated perfused rabbit proximal tubules (abst) 804
Norepinephrine infusion
at extremes of sodium intake in normal man (abst) 795
Norepinephrine release
into renal venous blood (abst) 830

Nucleotide precursor incorporation
in diabetic glomeruli in vivo (abst) 782

Obstructive uropathy
hyperkalemia and distal renal tubular acidosis in (abst) 926
Olecranon bursitis
in maintenance hemodialysis (abst) 890
Osmotic water flow
multiple pathways for (abst) 870
Osteitis fibrosa
vitamin D metabolite effect on (abst) 222
Osteocytes
thiazide induced increased density of (abst) . . . 827
Oxalate
diuretics, uric acid, Ca effects on 572
in serum measured by isotopic clearance technique (abst) 236
removed by dialysis and hemoperfusion (abst) . 229
Oxalosis
pyridoxine therapy of (abst) 243
in uremic stage (abst) 653

Parasitosis
circulating immune complexes and C3d in human 9
Parathyroid extract
relaxing effect of (abst) 860
Parathyroid gland response
to beta-adrenergic agents (abst) 917
Parathyroid hormone
cimetidine effect on (abst) 951
effect on phosphate transport in canine renal brush border membrane vesicles (abst) 818
lack of direct effect of 1,25-dihydroxy-cholecalciferol on secretion of (abst) 816
metabolism of intact (abst) 867
pseudohypoparathyroidism urinary responses to (abst) 935
renal tachyphylaxis to (abst) 806
sodium handling and heterogenous cyclic AMP during (abst) 817
Parathyroid responsiveness
bi-terminal and carboxy-terminal PTH assays in acute (abst) 917
Parathyroidectomy
osteomalacia with hypercalcemia following subtotal (abst) 952
Penicillamine nephropathy
corticosteroid prevention of (abst) 900
Peptide hormones
dialysis therapy and (abst) 238
Peptides
renal tubular processing of (abst) 831
Peritoneal fluid eosinophilia
in maintenance peritoneal dialysis (abst) 889
Peritoneal permeability
protamine sulfate and (abst) 880
Peritonitis in CAPD
new sterile connecting system to avoid (abst) . . 217
Peritubular membrane potentials
in isolated perfused proximal tubule of rabbit (abst) 806

Peroxidase, horseradish
renal reabsorption and excretion of 404
pH
effect on cAMP-induced water movement in toad bladder (abst) 807
Phosphate depletion
thiazide effect on urinary and serum calcium during (abst) 807
Phosphate deprivation
differential effects of (abst) 855
Phosphate retention
parathyroid hormone in rats with acute uremia as caused by 552
Phosphate transfer
during hemodialysis and hemofiltration (abst) . . 883
Phosphate transport
glucose inhibition of (abst) 805
membrane alkaline phosphatase activity and (abst) 840
parathyroid hormone effect on (abst) 818
Phospholipase activity
in ureter obstructed rabbit kidney (abst) 787
Phosphorus depletion
phosphaturia after parathyroid hormone (abst) 859
Phosphorylation, 2-deoxyglucose
evaluation of ATP, ADP levels in intact red blood cells by (abst) 802
Piretanide
diuretic activity of (abst) 98
Plasma catecholamines and blood pressure
during hemodialysis or diafiltration (abst) 650
Plasma prorenin
chromatographic isolation of totally inactive (abst) 791
Plasma renin concentration
potassium and ADH effect on (abst) 833
Plasma separation
in Goodpasture's syndrome and multiple myeloma (abst) 239
Platelet aggregation
serum from hemodialysis patients and (abst) . . 779
Podocytes
anionic charge behavior of (abst) 861
Polycation protamine
effect on glomerular permeability to albumin and ferritin of (abst) 856
Polycystic disease
ductal obstruction in adult 743
Polydipsia effect
on renal function (abst) 871
Polytetrafluoroethylene arteriovenous fistulas
access site infection in (abst) 897
Polytetrafluoroethylene grafts
used for hemodialysis (abst) 226
Postobstructive diuresis
renal catecholamine depletion and renal denervation and (abst) 861
Potassium *see also* K
adaptation mechanism of (abst) 820
Potassium depletion
gentamicin nephrotoxicity risk and (abst) 849
renal prostaglandins and (abst) 874

vasopressin-sensitive cyclic AMP system and (abst) 784
Potassium deprivation
suppression of potassium-recycling in renal medulla by short-term 694
Potassium excretion
aldosterone steady-state effects on (abst) 845
Potassium extrarenal transfer (abst) 835
Potassium homeostasis
epinephrine effect on (abst) 917
Potassium infusion
effect on potassium recycling in renal medulla (abst) 803
Prednisolone
MLR inhibition and (abst) 742
Prolactin
in chronic renal failure, hemodialysis and transplant patients (abst) 235
Prorenin
angiotensin II and saralasin effect on (abst) . . . 795
Prostacyclin
as defense mechanism against thrombotic occlusions (abst) 652
effect on glomerular hemodynamics (abst) . . . 835
effect on transepithelial potential difference in cortical collecting tubule of (abst) 822
use during hemoperfusion (abst) 244
Prostaglandin
contributions to glomerulotubular balance of (abst) 821
effect on ADH-dependent osmotic water permeability and Na efflux coefficient (abst) . . . 839
and renin interactions (abst) 836
and thromboxane synthesis by glomeruli (abst) . 793
Prostaglandin biosynthesis
by human kidney, in vitro (abst) 819
Prostaglandin cycloxygenase
cooxygenation by 688
Prostaglandin deficiency
sodium and potassium excretion in (abst) 850
Prostaglandin E excretion
high urine flow rate increases (abst) 845
Prostaglandin E_1
role during hypoxia (abst) 849
treatment of murine lupus nephritis (abst) 798
Prostaglandin E_2
urinary recovery and (abst) 834
Prostaglandin E_2 production
glomeruli and papilla alteration of (abst) 847
Prostaglandin E_2-sensitive adenylate cyclase
distribution along rat nephron of (abst) 841
Prostaglandin F_1 therapy
of murine chronic serum sickness (abst) 786
Prostaglandin inhibition
effect on cyclic AMP mediated renal vasodilation and renin release (abst) 795
effect on sodium excretion 532
effect on water excretion (abst) 874
Prostaglandin synthesis
by glomerular cultured cells (abst) 839
unilateral ureteral obstruction and (abst) 858
in uremic patients, unbalanced (abst) 651
vasopressin antidiuretic component stimulation of (abst) 869
Protein calorie malnutrition
oral amino-acid supplementation effect on (abst) 895
Protein, low-molecular-weight
filtration and reabsorption of endogenous 394
renal filtration, transport, and metabolism of . . 251
Protein synthesis
during compensatory renal growth (abst) 866
Proteinuria
acute reversible
polycation infusion induced (abst) 783
effect of inhibitors on angiotensin and catecholamine induced (abst) 781
protease inhibitor trasylol and (abst) 782
in schoolchildren (abst) 939
Proximal convoluted tubule
alpha-adrenergic stimulation and blockade of (abst) 831
chloride and bicarbonate permeability in superficial and deep (abst) 820
CO_2 kinetics across rabbit (abst) 836
determinants of volume reabsorption in rat (abst) 809
Na transport and acidification in rat (abst) 809
Proximal glomerulo-tubular balance
carbonic anhydrase role in (abst) 810
Proximal tubules
anion selectivities of (abst) 842
basolateral membrane of (abst) 838
bicarbonate handling (abst) 845
calcium action in (abst) 826, 834
chloride action in (abst) 812
dextran effects and protein digestion in 301
and inability to sustain pCO_2 gradient in vivo (abst) 827
ionic permselectivity of volume expansion-induced changes in rat (abst) 813
maleic acid effect on (abst) 846
pCO_2 acute change effect on in vitro (abst) . . . 822
pCO_2 gradient between rat star vessels and early and late (abst) 815
phosphate action in (abst) 807, 832
respiratory alkalosis and metabolic acidosis effect on rat (abst) 815
sodium-hydrogen exchange in (abst) 658
urate absorption from rat (abst) 843
Psammomys obesus
furosemide effect on (abst) 873
PVC hemodialysis tubes
migration of plasticizers from (abst) 222
Pyelonephritis
acute, mechanisms of tissue damage in (abst) . . 789
urinary angiotensin-converting enzyme activity in (abst) 649

Quartan malarial nephrotic syndrome
in children 64

Remnant kidneys
permselectivity properties of (abst) 787
Renal acetazolamide-insensitive
bicarbonate reabsorption (abst) 827
Renal acid-base equilibrium
spironolactone effect on (abst) 821
Renal acid-base homeostasis
in adrenalectomized patients (abst) 858

Renal allograft, *see also* Transplantation and Renal Transplantation
donor specific suppressor cells in (abst) 221
erythrocytes and survival of (abst) 214
gamma globulin and survival of (abst) 237
gastrointestinal complications during an ATG trial in (abst) 943
intensive plasma exchange as adjunct therapy in (abst) 941
peripheral blood lymphocytes in (abst) 941
value of (abst) 230
Renal allograft biopsy
improved method for 519
Renal allograft rejection
C-reactive protein in (abst) 91
IgA deficiency and (abst) 945
Renal allograft survival
pretransplant "T" cell levels and (abst) 241
prolongation of (abst) 234
Renal amyloidosis
DMSO treatment of (abst) 242
Renin-angiotensin-aldosterone system
in healthy infant and child 196
Renal artery reconstruction
(abst) 893
Renal artery stenosis
intraluminal dilatation of 531
Renal biopsy
arteriographic control of percutaneous (abst) . . 938
H and E stained frozen section pathologic evaluation of (abst) 916
Renal biopsy specimens
extracellular immunoproteins in formalin-fixed . 632
Renal blood flow
calcium role in autoregulation of (abst) 814
salt and autoregulation of (abst) 792
Renal candidiasis
pathogenesis of (abst) 781
Renal cell volume regulation
without ouabain insensitive pumps (abst) 843
Renal consultation
content and impact of (abst) 936
Renal cortical interstitium
heterogeneity of (abst) 844
Renal cortical lymphatic system
distribution and density of canine 470
Renal cortical mitochondrial oxidative phosphorylation
gentamicin inhibitory effect on (abst) 776
Renal cortical mitochondrial respiration
cis-diamminedichloroplatinum inhibitory effect on (abst) 862
Renal cysts
antibiotic penetrance in (abst) 934
Renal disease
in acute *Plasmodium falciparum* infection . . . 44
cimetidine inhibition of iPTH in chronic (abst) . 918
due to schistosomiasis 156
end-stage
analgesic nephropathy as cause of (abst) . . . 933
analgesic nephropathy in etiology of (abst) . . 930
coronary artery bypass surgery and (abst) . . 885
epidemiologic approach to planning in (abst) . 901
proteinuria in (abst) 933
recovery from (abst) 886
survival and (abst) 949
glomerular microfibrils in 497
ionized calcium in (abst) 935
kidney tissue, blood, and urine fibrinolytic activity decrease as (abst) 652
lymphoma, cryoglobulinemia, and 522
nonglomerular, proteinuria mechanism in 416
serum albumin concentration and tubular reabsorption of glucose in 546
serum immunoreactive trypsin in (abst) 237
Renal epithelial monolayer
in vivo "culture" of (abst) 823
Renal failure
acute
among Africans and Indians in South Africa (abst) 90
carbamazepine induced (abst) 877
chromate induced (abst) 877
cis-diamminedichloroplatinum induced (abst) 772
clonidine and (abst) 859
dopamine plus furosemide in prevention of . . 158
endotoxemic (abst) 774
gentamicin-induced (abst) 771, 773, 778
glomerular alterations in ischemic model of (abst) 771
glycerol induced (abst) 773
ibuprofen induced (abst) 876
after immersion in fresh water (abst) 876
immunohistochemical localization of complement in ischemic model of (abst) 775
ionized calcium role in (abst) 772
kidney function recovery after (abst) 227
loss of blood flow autoregulation in (abst) . . . 850
low fractional sodium excretion and (abst) . . 876
mannitol infusion and 774
mercury ingestion and (abst) 875
and microangiopathic hemolytic anemia (abst) 653
non-steroidal anti-inflammatory drug induced (abst) 875
pancreatitis, pseudocyst and (abst) 875
protection by angiotensin converting enzyme inhibitor (abst) 785
protective effect of splenectomy against (abst) 775
radionuclide renal scintiscans and flow stuides in (abst) 877
reduced mortality in treatment of (abst) 87
saline loading effect on glycerol-induced (abst) 771
sodium-chloride-induced protection in nephrotoxic 481
thyroparathyroidectomy, PTH and cAMP infusion effect on PO_4 excretion in (abst) . . . 774
after ticrynafen ingestion (abst) 935
transtubular inulin backleak in (abst) 878
tubular cell injury relation to protection against (abst) 778
urine dilution and concentration following (abst) 956
urine pH in prevention and therapy of (abst) . 877
aluminum accumulation in (abst) 230
chronic
altered prostaglandin-mediated adherent cell suppressor activity in (abst) 913
enteral alimentation in (abst) 865

erythroid colony forming cells in (abst) 923
frusemide treatment in (abst) 88
immunologic reactivity in (abst) 653
myelofibrosis in children with (abst) 952
neutron activation analysis and (abst) 241
peritoneal fluid absorption in (abst) 850
serum cholate conjugates in (abst) 951
survival analysis in (abst) 930
vitamin D in (abst) 226
compensated
endocrine system and (abst) 237
coronary artery disease in diabetics with (abst) . 949
diabetic
CAPD and (abst) 221
intravenous total parenteral nutrition in (abst) 950
paradoxical insulin changes and (abst) 881
dichromate-induced (abst) 776
end-stage
continuous ambulatory peritoneal dialysis treatment of (abst) 98
peritoneal dialysis in (abst) 880
idiopathic postpartum (abst) 91
irreversible
after indomethacin in steroid resistant nephrosis (abst) 96
ischemic
glomerular filtration in (abst) 776
neonatal
diagnostic index usefulness and (abst) 876
oliguric
induced by radiocontrast drugs (abst) 878
polyuric acute
cis-diamminedichloroplatinum induced (abst) 775
porphyrin in (abst) 86
postischemic acute
recovery from 113
role of tubular obstruction, thromboxane synthesis, and outer medullary microvascular injury in (abst) 777
salt diet effect on rat recovery from (abst) . . . 773
rhabdomyolysis-acute
creatinine and (abst) 777
ultrasound role in acute posttransplant (abst) . . 944
Renal function
chronic aluminum ingestion effect on (abst) . . . 830
effect on dialysis requirements (abst) 239
gentamicin effect on (abst) 772
and lithium therapy 532
in model of medullary necrosis 533
in sickle cell patients (abst) 934
recovery of, in obstructive uropathy (abst) . . . 923
Renal hemodynamics
angiotensin II effect on (abst) 921
arterial pressure control and (abst) 793
captopril and (abst) 909
Renal hormone
role in vasodilatory effect of mannitol (abst) . . . 774
Renal infection
immunobiologic factors in pathogenesis of . . . 665
Renal insufficiency
hospital-acquired (abst) 875
hyperkalemia in (abst) 925
nutritional status and chronic supplementation in children with chronic (abst) 950
periodontal disease in experimental (abst) 902
reduced plasma concentration of $1,25(OH)_2D$ in (abst) 922
sodium intake reduction and 590
urea secretion in (abst) 918
Renal lesions
malaria and 3
Renal medulla
potassium-recycling suppression in 704
Renal mitochondrial oxidative phosphorylation
gentamicin inhibition of (abst) 860
Renal osteodystrophy
in children (abst) 218
dihydrotachysterol in (abst) 891
$1,25(OH)_2$ vitamin D_3 therapy for (abst) 953
softened or deionized water and (abst) 87
Renal osteopenia
vitamin D analogues in assessment of (abst) . . . 219
Renal papilla cells
solute and H_2O content of (abst) 805
Renal papillary epithelial cells
urea-dependent transmembrane potential difference and (abst) 840
Renal papillary necrosis (abst) 931
Renal phosphate handling
renal brush border membrane transport and enzyme properties and (abst) 823
Renal prostaglandin E_2 biosynthesis
dependence on angiotensin II (abst) 791
Renal prostaglandin-metabolism
salt and water balance and (abst) 825
Renal prostaglandin system
desamin-arginine vasopressin effect on diabetes insipidus (abst) 871
Renal reflux scarring cystometrography
tissue types and (abst) 233
Renal revascularization
to preserve kidney function (abst) 908
Renal scanning
with 99mTc (abst) 916
Renal sodium retention
in nephrotic syndrome in rats 561
Renal stone epidemiology
a 25-year study 624
Renal transplant biopsies
interstitial hemorrhage in (abst) 946
Renal transplant rejection
B-2 microglobulin in diagnosis of (abst) 947
Lewis antigens and (abst) 96, 221
prognosis (abst) 940
steroid therapy of (abst) 942
Renal transplantation *see also* Transplantation and Renal allografts
antisuppressor T cell antibody and (abst) 944
antithymocyte globulin effect on humoral immunity in (abst) 942
dermatological findings and (abst) 227
diabetes mellitus following (abst) 946
endothelial antibodies in (abst) 235
low dose steroid and (abst) 231
orthopedic complications of (abst) 233

pancreatic beta-cell function following (abst) . . 947
pancreatic polypeptide following (abst) 947
parathyroid function following (abst) 947
prednisone-induced catabolism following (abst) . 951
proteinuria in (abst) 943
psychiatric and sociocultural reactions to (abst) . 86
sodium excretion after 167
upper extremity acronecrosis in juvenile onset diabetics after (abst) 948
urinary cytology and acute rejection after (abst) . 658
urinary sodium excretion and blood pressure after (abst) 943
without acathiotrine (abst) 238
Renal tubular acidosis
after kidney transplantation (abst) 655
Renal tubular dysfunction
in medullary sponge kidney (abst) 922
Renal tubular secretion
of norepinephrine, mechanism of (abst) 825
Renal tubular transport
of antibiotics (abst) 903
catabolism of proteins and peptides and 271
effect of 25-hydroxyvitamin D3 on (abst) 832
of gentamicin in rat 440
Renal tubule cell volume
metabolic inhibitor effect on (abst) 826
Renal vascular reactivity
adenosine effect on (abst) 838
Renal vascular resistance
thromboxane A_2 regulation of (abst) 847
Renal vein constriction
effect on localization of immune complexes in kidney 681
Renin
and prostaglandin interactions in isolated rat glomeruli (abst) 836
Renin-angiotensin system
role in arterial hypertension (abst) 656
Renin inhibition
by HCl (abst) 825
Renin release
barium as calcium substitute in control of (abst) . 794
cation modification of (abst) 805
inactin effect on (abst) 796
and juxtaglomerular apparatus renin in response to hemorrhage (abst) 829
by pentobarbital anesthesia (abst) 808
theophylline blockade of decrease in (abst) . . . 838
Renin responses
to sodium depletion, propranolol and indomethacin (abst) 794
Renin secretion
after aortic constriction in range of autoregulation, renal nerve modulation of (abst) 795
effect of acid, trypsin, cold treatment, and renin-plasma interaction on rat kidney (abst) 658
by isolated rat kidney 533
Rheogenic active Na-K transport
potassium stimulation of (abst) 835

Salt retention mechanism
in dogs with chronic thoracic inferior vena cava constriction (abst) 851
Sarcoidosis
chronic hypernatremia and hypopituitarism in (abst) 97
Schizophrenia
dialytic treatment in chronic (abst) 651
Scleroderma renal crisis
captopril treatment of (abst) 910
Sjogren's syndrome
chronic renal failure and (abst) 939
Sodium, *see also* Na
Sodium balance maintenance
aldosterone and natriuretic factor in (abst) . . . 99
Sodium excretion
during water diuresis (abst) 820
Sodium permeability
lanthanum effect on (abst) 819
Sodium retention
mineralocorticoid-dependent mechanism in pathogenesis of (abst) 849
Sodium transport
amiloride resistance in toad bladder (abst) 807
histamine effect on (abst) 819
interrelations between cAMP, cGMP and Ca^{2+} in water (abst) 818
Sodium vanadate effect, *see also* Vanadate
on whole kidney and single nephron function (abst) 820
Somatostatin
kidney role in handling (abst) 91
Spironolactone effect
on renal and systemic acid-base equilibrium (abst) 821
Subepithelial immune deposit formation
antibody size effect on (abst) 801
Substrate decarboxylation
by isolated single nephron segments (abst) . . . 824
Substrate oxidation
measurement (abst) 865
Syndrome of inappropriate secretion of ADH (abst) 956

Tamm-Horsfall protein
pathophysiology of 279
urinary excretion of (abst) 93
Thallium 201 imaging
as stress test of latent coronary disease (abst) . . 890
Theophylline-induced leaky states (abst) 812
Thiazide induced hyponatremia (abst) 918
Transplantation, *see also* Renal Transplantation
ADCC and natural killer cell activity in kidney (abst) 945
allograft function, circaseptan rejection rhythms, and proteinuria in (abst) 940
antibodies, cytotoxic (abst) 242
blood transfusions in living related (abst) 948
cadaveric, rapid HLA-D matching for (abst) . . . 944
cadaveric retransplantation (abst) 240
in children with end-stage renal disease of urologic origin (abst) 945
FE_{Na} is diagnosis of rejection after kidney (abst) 941
followup on graft survival (abst) 225
hypertension and, renin-angiotensin (abst) . . . 944

kidney functional pattern before (abst) 237
linear models for graft survival 232
paired necrographs (abst) 228
phosphate handling (abst) 224
thermography in (abst) 227
Triiodothyronine, tissue
hypothyroidism in uremic rat model (abst) . . . 867
Tuberous sclerosis
cystic renal lesion of (abst) 938
Tubular necrosis
antibody to Tamm-Horsfall protein after acute (abst) 878
Tubule fluid-to-plasma ultrafiltrate chloride ratio (abst) 842
Tubulogomerular feedback response
during reduced renal perfusion pressure (abst) . 855
PGI_2 restoration of (abst) 835

Ultrafiltration
hematologic studies during isolated (abst) 889
sympathetic activity and hemodynamics in (abst) 891
Urea clearance
peritoneal dialysate flow rate and (abst) 884
Urea nitrogen
appearance (abst) 953
Uremia
acute, phosphate retention and 552
amino acid infusion and (abst) 868
augmented polymorphonuclear leukocyte chemiluminescence and (abst) 955
betacell activity in, (abst) 653
body temperature and (abst) 954
bone disease (abst) 218, 856
bone formation modulators in (abst) 924
Ca absorption in (abst) 954
catechol-O-methyltransferase in (abst) 954
chronic
duodenal cap in (abst) 98
lymphocyte transformation in (abst) 880
effect on insulin metabolism 433
erythrocyte hexose-monophosphate shunt in (abst) 244
glucose intolerance and insulin binding relationship to monocytes in (abst) 883
glucose intolerance in (abst) 952
HDL cholesterol as cardiovascular risk factor in (abst) 94
hemodialysis of acetaminophen in (abst) 893
hypogonadism, zinc effect on (abst) 893
immunosuppressive factor in serum (abst) . . . 800
K^+ balance and N metabolism in (abst) 953
plasma keto analogues in (abst) 230
production rate of distorted protein profile of (abst) 780
propranolol and metroprolol effect on (abst) . . . 219
reduced end-organ response to norepinephrine in (abst) 951
systemic lupus erythematosus and development of (abst) 884
thrombocyte calcium content correction in (abst) 953
vitamin D analog effect on muscle protein catabolism in (abst) 866

Uremic pericarditis
indomethacin and (abst) 899
Uremic peripheral neuritis
hemoperfusion treatment of (abst) 235
Uremic pruritus
ultraviolet phototherapy in (abst) 239
Ureteroneocystostomy
anterior extravesical (abst) 949
Urethral syndrome (abst) 660
Uridine nucleotide
generation in isolated diabetic glomeruli (abst) . 782
Urinary acid-base equilibrium
Ca^{++} loading effect on plasma and (abst) 821
Urinary acidification
HCl perfusion and (abst) 839
inhibition by cholinergic agent carbachol (abst) . 803
microtubule role in (abst) 847
Urinary β_2 microglobulin
aminoglycosides and (abst) 879
Urinary bladder
vasopressin and serosal hypertonicity effect on . 695
Urinary concentrating mechanism
arginine-vasopressin, cAMP, and prostaglandin F_2 interaction in (abst) 872
recent formulations of 537
Urinary infection
management of resistant 204
Urinary matrix calculi
in patients on maintenance hemodialysis 722
Urinary tract carcinoma
analgesic abuse as risk factor for (abst) 930
Urinary tract infections
β_2-microglobulin excretion in (abst) 937
renal injury and (abst) 95
Urine
alkaline, Pco_2 diurnal variations in 533
in distance runners (abst) 932
low-molecular-weight natriuretic substance in normal 710
pulsatile movement, through papillary collecting ducts (abst) 830
tissue antigens in normal and pathologic 337
vasopressin, in nephrogenic diabetes insipidus (abst) 956
zinc handling and amino acids (abst) 818

Vanadate, *see also* Sodium vanadate
inhibition of renal HCO_3 and PO_4 reabsorption (abst) 844
renal response to (abst) 851
Vascular endothelium role
in bleeding tendency of uremic patients (abst) . . 652
Vasodilator effect
on peritoneal clearance of creatinine and insulin during dialysis 459
Vasopressin
cellular calcium uptake and hydroosmotic response to (abst) 869
decreased response to (abst) 870
Vasopressin binding
NaCl and ATP modulation of (abst) 804

Vasopressin effect
on adenylate cyclase activity and on cyclic AMP levels in medullary thick ascending limb of Henle's loop (abst) 812
on adenylate cyclase by endogenous prostaglandins (in medullary collecting tubules) (abst) . . 822
on chloride transport by medullary thick ascending limbs of Henle's loop perfused in vitro (abst) 818
Vasopressin induced hydroosmotic effect
inhibition of (abst) 814
Vasopressin mediated water flow
kallikrein-kinin system and (abst) 870
Vasopressin receptors
conformational categories of (abst) 870
Vasopressin-release
emetic reflex influence on 729
Vasopressin role
in water imbalance of sick newborn (abst) 956
Vasopressin secretion
decreased osmotic threshold of (abst) 871
Vasopressin stimulated water transport
carbachol as inhibitor of (abst) 868
dithiothreitol and dehydroascorbic acid modulation of (abst) 869
thromboxane and (abst) 870
Virus-infected macrophages
age-dependent cytotoxic T lymphocyte response to (abst) 797
Voltage dependent distal acidification defect
amiloride induced (abst) 847

Water flow
vasopressin- and hypertonicity-induced (abst) 874
Water permeability
ADH-induced osmotic (abst) 823
Water transport
abdominal skin and (abst) 872
histamine effect on (abst) 819
Wegener's disease
dialysis and transplantation in (abst) 98
Wegener's granulomatosis
clinicopathologic study of (abst) 214

Zinc metabolism
in chronically azotemic rat (abst) 866